

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number:

0 404 190
A1

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 90111903.2

(51) Int. Cl.⁵: **C07D 471/04, C07D 487/04,
C07D 513/04, C07D 498/04,
A01N 43/90, //(C07D471/04,
235:00,221:00)**

(22) Date of filing: 22.06.90

(30) Priority: 23.06.89 JP 161507/89
27.10.89 JP 280358/89
27.04.90 JP 114318/90

(43) Date of publication of application:
27.12.90 Bulletin 90/52

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI LU NL SE


(71) Applicant: **TAKEDA CHEMICAL INDUSTRIES,
LTD.**
3-6, Doshomachi 2-chome Chuo-ku
Osaka(JP)

(72) Inventor: Mitsudera, Hiroyuki
31-8, Machikaneyama-cho
Toyonaka, Osaka 560(JP)
Inventor: Konobe, Masato
50-1, Yamadaminami
Suita, Osaka 565(JP)
Inventor: Ishida, Yasuo
A-410, 45 Yamadaminami
Suita, Osaka 565(JP)
Inventor: Matsuura, Kazuho
8-59, Yamabana-itchodacho
Sakyo-ku, Kyoto 606(JP)

(74) Representative: Lederer, Franz, Dr. et al
Lederer, Keller & Riederer, Patentanwälte,
Lucile-Grahn-Strasse 22
D-8000 München 80(DE)

(54) Condensed heterocyclic compounds, their production and use.

(57) A condensed heterocyclic compound of the general formula:



wherein Q is a condensed heterocyclic group having a nitrogen atom in the bridgehead which is unsubstituted or substituted, X is a hydrogen atom or a group attached through C, O, S or N, and Y is an electron attractive group, or its salt which is useful as agricultural chemicals.

EP 0 404 190 A1

Condensed Heterocyclic Compounds, Their Production and Use

BACKGROUND OF THE INVENTION

5 1. Field of the Invention

This invention relates to novel condensed heterocyclic compounds or salts thereof, intermediates thereof, method for preparing them and farming and gardening fungicide containing them.

10

2. Description of the Prior Art

It has been known that some kinds of amide compounds possess fungicidal activity against pathogenic fungi causing various kinds of plant blight. For instance, compounds described in Japanese Patent
15 Unexamined Publication No. 135,364/1988, EP 61836A and GB 2190375A exhibit effects against downy mildew fungi of a vine and cucumber and pathogenic fungi of a tomato and potato. However, it is hard to say that those compounds exhibit sufficient controlling effects and safety.

Thus, it is desired to conquer the aforementioned defects, namely, to provide compounds possessing excellent control effects against plant blight, method for preparing those compounds and agent for
20 controlling plant blight containing those compounds.

Downy mildew and other blight of vegetables and fruit trees are liable to happen and spread in a time of much rain. Accordingly, it is required to provide compounds which are not washed away by rain (rain-resisting quality) and exhibit excellent effect for controlling and curing plant blight, do not damage the cultivating plants and show less toxicity to warm-blooded animals and fish, and also to provide a simple and
25 easy method for preparing those compounds in high yield and to provide a useful agricultural chemical containing those compounds.


SUMMARY OF THE INVENTION

30

The present inventors have studied intensively to attain the aforementioned problems, and succeeded in preparation of condensed heterocyclic compounds of the following general formula (I) and their salts and found that these compounds exhibit excellent effects for controlling various kinds of plant blight, especially
35 downy mildew and blight, possess excellent rain-resisting quality, do not damage the plants and are less toxicity against warm-blooded animals and fish and that those compounds can be prepared by an industrially advantageous method.

Thus, the present invention relates to a condensed heterocyclic compound of the general formula:


40




45

wherein Q is a condensed heterocyclic group having a nitrogen atom in the bridgehead which is unsubstituted or substituted, X is a hydrogen atom or a group attached through C, O, S or N, and Y is an electron attractive group, and its salt.

50 This invention also relates to a method for preparing a condensed heterocyclic compound (I) or its salt by reacting a compound of the general formula:




wherein Q has the same meaning as defined in the above formula (I), and Z is a leaving group, or its salt with a compound of the general formula:




wherein X and Y are each as defined in the above formula (I), or its salt.

And further, this invention relates to a farming and gardening fungicide containing a condensed heterocyclic compound of the general formula (I) or its salt.

According to one aspect, the present invention provides a condensed heterocyclic carboxylic acid compound of the general formula:



wherein Q¹ is a condensed heterocyclic group having a nitrogen atom in the bridgehead as follows




in which R¹ is an C₁₋₆ alkyl, halogen, C₁₋₄ alkoxy, C₁₋₄ alkylthio, C₆₋₁₀ aryloxy, C₆₋₁₀ arylthio, alkoxycarbonyl, phenyl, substituted phenyl or aromatic heterocyclic group; R² and R³ are a hydrogen, C₁₋₆ alkyl, halogen, nitro, amino, sulfo, mono- or di-alkylsulfamoyl, alkoxycarbonyl, formyl, cyano, phenyl, substituted phenyl or aromatic heterocyclic group, provided that when Q¹ is




and R¹ is COOCH₂CH₃, either one of R² and R³ is another group than hydrogen atom, and Z is a leaving group; or its salt.


According to another aspect, the present invention provides a process for preparing a compound of the general formula:



wherein Q² is a group of the general formula:




in which R¹, R² and R³ have the same meanings as defined above or its salt which comprises reacting a compound of the general formula:




30 wherein the ring (A) is a pyridine, pyridazine, pyrimidine or pyrazine group which is unsubstituted or substituted by an C₁₋₆ alkyl, halogen, nitro, amino, sulfo, mono- or di-alkylsulfamoyl, alkoxycarbonyl, formyl, cyano, phenyl, substituted phenyl or aromatic heterocyclic group, and Z is a leaving group, or its salt

with a compound of the general formula:



40 or




wherein W is a halogen atom, and R¹ and R² have the same meanings as defined above.


The compounds (I) or their salts of this invention have a novel structure characterized by the combination of a specific group, namely, a condensed heterocyclic group having nitrogen atom in the bridgehead and the carbonyl group, which is different from the known amide compounds. The compounds of this invention have merits that they exhibit an excellent control effect for downy mildew and blight, possess excellent water-resisting quality, do not damage the plants and are less toxicity against warm-blooded animals and fish.

PREFERRED EMBODIMENT OF THE INVENTION

In the above formula (I) and (II), the symbol Q means a condensed heterocyclic group having a nitrogen atom in the bridgehead which is unsubstituted or substituted. The condensed heterocyclic group having at least a nitrogen atom in the bridgehead means a condensed heterocyclic group where the atom(s) of the head or end of the bridge bond, namely, both of them or either of them is a nitrogen atom, which is not ionized. The condensed heterocyclic group having a nitrogen atom in the bridgehead represented by the Q is a group which is formed by removing one hydrogen atom bonded to a ring-constituting carbon atom at a position other than the bridgehead of a condensed heterocyclic compound shown, for example, by the general formula:



wherein the rings a and b are each a N-containing heterocyclic ring which is unsubstituted or substituted. Those condensed heterocyclic groups can be represented, for example, by the general formula:



wherein — means a chemical bond, and the other symbols are each as defined above. The preferred one is a group shown by the above left formula.


The N-containing heterocyclic ring represented by the ring a and ring b means a 4 to 8-membered, preferably 5 to 6-membered heterocyclic ring containing 1 to 4 nitrogen atom(s), which may further contain 1 to 3 oxygen atom(s) and/or 1 to 3 sulfur atom(s) optionally mono- or di-oxidized. Such heterocyclic ring may further be condensed with a 5 to 6 membered aliphatic cycle (e.g. cyclopentane, cyclohexane), aromatic cycle (e.g. benzene or naphthalene) or heterocycle (preferably 5 to 6-membered heterocycle).

Among these condensed heterocyclic rings, heterocyclic groups formed by condensation of 5-membered ring and 6-membered ring are preferable.


In the above formula, the ring a is preferably a 5-membered heterocycle containing 1 to 3 nitrogen atoms, and the ring b is preferably a 6-membered heterocycle containing 1 to 2 nitrogen atoms or a 5-membered heterocycle containing 1 to 2 nitrogen atoms and 1 sulfur atom optionally mono- or di-oxidized.

The rings a and b may be substituted by the same or different one to three substituents (B¹, B², B³) as defined below.

Specifically, the group represented by the general formula:




includes the groups shown, for example, the general formulae:



wherein A is a group forming a condensed ring at the [1,2] positions of the imidazole ring, A' is a group forming a condensed ring at the [1,5] positions of the imidazole ring, A'' is a group forming a condensed ring at the [1,5] positions of the pyrazole ring, A''' is a group forming a condensed ring at the [1,2] positions of the pyrrole ring, A'''' is a group forming a condensed ring at the [3,4] positions of the triazole ring, and B¹, B² and B³ are each as defined below.

The group A, A', A'', A''' or A'''' contains 1 to 4, preferably 3 to 4 carbon atoms as the ring-constituting atom and may further contain 1 to 3 of nitrogen, oxygen and/or sulfur atom(s) (which may be in mono- or di-oxidized form).

Among the above condensed heterocyclic groups, the groups represented by the general formulas:




are preferable.

The group represented by the general formula:



is more preferable.


Examples of the condensed rings represented by



5

as the skeleton of the group of the general formula





10







15

include:

20



25



30


35

40

45


50

55




Examples of the condensed rings represented by

5






10 as the skeleton of the group of the general formula:

15





are:


20



25




and



30

Examples of the condensed rings represented by


35



40

as the skeleton of the group of the general formula:



45




50

are:


55




and




Examples of the condensed rings represented by




as the skeleton of the group of the general formula:




are:






Examples of the condensed rings represented by




as the skeleton of the group of the general formula:



are:




and






More specifically, these condensed heterocyclic groups include imidazo[1,2-a]pyridine, imidazo[1,2-a]pyrimidine, imidazo[1,2-c]pyrimidine, imidazo[1,2-a]pyrazine, imidazo[1,2-b]pyridazine, imidazo[1,2-b](1,2,4)-triazine, imidazo[2,1-a]imidazole, imidazo[1,2-b]pyrazole, imidazo[2,1-b]thiazole, imidazo[2,1-b](1,3,4)thiazole, 2,3-dihydroimidazo[2,1-b]thiazole, pyrazolo[1,5-a]pyrimidine, pyrazolo[5,1-a]thiazole, pyrazolo[1,5-a]pyridine, pyrrolo[1,3-b]pyridine, imidazo[1,5-a]pyridine and (1,2,4)-triazolo[3,4-b]thiazole.


On the other hand, the group represented by the general formula:



includes the groups represented, for example, by the general formulae:



and




wherein B¹ and B² are each as defined below.

More specifically, 6H-(1,2,4)triazolo[1,2-b](1,2,3,4)tetrazyl, 1H-(1,2,4)triazolo[1,2-a](1,2,4)triazyl, (1,2,3)-triazolo[2,1-a](1,2,3)triazin-4-ium, (1,2,4)triazolo[1,2-a]pyridazin-4-ium and 6H-pyrazolo[1,2-a](1,2,4,5)tetrazyl are exemplified.

The substituents B¹, B² and B³ on the condensed heterocyclic group for Q may be the same or different each other. Examples of the substituents are hydrogen atom, nitro, amino, hydroxyl, cyano, C₁₋₃ acyl (formyl, etc.), carbamoyl, carboxyl, alkoxycarbonyl (e.g., C₁₋₄ alkoxycarbonyl such as methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, isopropoxycarbonyl, etc.), sulfo, halogen (chlorine, bromine, iodine, fluorine, etc.), C₁₋₄ alkoxy (methoxy, ethoxy, propoxy, iso propoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, etc.), C₆₋₁₀ aryloxy (phenoxy, etc.), C₆₋₁₀ arylcarbonyl (benzoyl, etc.), C₆₋₁₀ aryl (phenyl,

etc.), C₇₋₁₀ aralkyl (benzyl, phenethyl, etc.), C₃₋₇ cycloalkyl (cyclohexyl, etc.), C₁₋₄ alkylthio (methylthio, ethylthio, propylthio, isopropylthio, butylthio, iso-butylthio, sec-butylthio, tert-butylthio, etc.), C₆₋₁₀ arylthio (phenylthio, etc.), C₇₋₁₀ aralkylthio (benzylthio, etc.), mono- or di-alkylsulfamoyl (e.g., mono- or di-C₁₋₄ alkylsulfamoyl such as mono- or di-methylsulfamoyl, mono- or di-ethylsulfamoyl, mono- or di-n-propylsulfamoyl), C₁₋₆ alkyl (methyl, ethyl, propyl, isopropyl, pentyl, hexyl, etc.), substituted phenyl (mono-, di-, tri or tetra-halogen-substituted phenyl such as 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2-fluorophenyl, 4-bromophenyl, 2,3-dichlorophenyl, 2,4-dichlorophenyl, 2,6-dichlorophenyl, 2,4-difluorophenyl, 2,6-difluorophenyl, etc., mono-, di-, tri or tetra-C₁₋₄ alkyl-substituted phenyl such as 2-methylphenyl, 3-methylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 2,4-dimethylphenyl, 2,5-dimethylphenyl, 3,4-dimethylphenyl, 2,5-diethylphenyl, 2,4,6-trimethylphenyl, etc., mono-, di-, tri- or tetra-C₁₋₄ alkoxy-substituted phenyl such as 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 3,4-dimethoxyphenyl, etc., mono-, di-, tri- or tetra-C₁₋₄ alkylthio-substituted phenyl such as 2-methylthiophenyl, 3,4-dimethylthiophenyl, etc., 2-chloro-4-nitrophenyl, 4-nitrophenyl, 2-methyl-4-aminophenyl, 2-bromo-4-nitrophenyl, 2-nitro-4-methylphenyl, etc.), aromatic heterocyclic group (5 or 6 membered heterocyclic group such as pyridyl, furyl, thienyl, thiazolyl, etc.). Especially, one of B¹, B² and B³ is preferably C₁₋₆ alkyl, phenyl or substituted phenyl.

Q¹ in the above mentioned general formula (IV) means a condensed heterocyclic group having a nitrogen atom in the bridgehead shown by the following formula:



The substituents R¹, R² and R³ are the same or different and have the same meanings as mentioned above but either one of R² and R³ is a group other than hydrogen atom when Q¹ is



and R¹ is COOCH₂CH₃.

Examples of the substituent R¹ include the C₁₋₆ alkyl, halogen, C₁₋₄ alkoxy, C₁₋₄ alkylthio, C₆₋₁₀ aryloxy, C₆₋₁₀ arylthio, alkoxycarbonyl, phenyl, substituted phenyl or aromatic heterocyclic group as stated in the above B¹, B² and B³. Examples of the substituents R² and R³ include hydrogen, nitro, amino, sulfo,

formyl, cyano or phenyl group, and also the C₁₋₆ alkyl, halogen, mono- or di-alkylsulfamoyl, alkoxycarbonyl, substituted phenyl or aromatic heterocyclic groups as stated in the above B¹, B² and B³. The substituent R¹ is preferably phenyl or a substituted phenyl.

Preferable ones of Q¹ are Q' or Q'' as described below.

5 The symbol X in the general formula (I) is a hydrogen atom or a group attached through C, O, S or N atom. The group attached through a C atom may be an alkyl, alkenyl, haloalkyl, cycloalkyl, cycloalkenyl, aryl or aralkyl group or an aromatic heterocyclic group having a chemical bond at a carbon atom; the group attached through an O atom may be an alkoxy, aryloxy or aralkyloxy group; the group attached through a S atom may be an alkylthio, arylthio or aralkylthio group; and the group attached through a N atom may be an alkylamino, arylamino or aralkylamino group or an aromatic heterocyclic group having a chemical bond at a N atom.

The above alkyl group and alkyl moiety of the haloalkyl, alkoxy, alkylthio and alkylamino groups include a straight or branched one containing 1 to 10 carbon atoms such as methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, sec-pentyl, isopentyl, neopentyl, n-hexyl, isohexyl, n-octyl, n-decyl and the like.

The above alkenyl group may be one containing 2 to 4 carbon atoms such as vinyl, allyl, 2-methyl, 3-methyl, 3-butenyl or the like.


The above cycloalkyl group may be a 3- to 6-membered one such as cyclopropyl, cyclopentyl, cyclohexyl or the like.

20 The above cycloalkenyl group may be a 3- to 6-membered one such as cyclopropenyl, cyclopentenyl, cyclohexenyl or the like.


The above aryl group and aryl moiety of the aryloxy, arylthio and arylamino groups may be one containing 6 to 10 carbon atoms such as phenyl, tolyl, xylyl, naphthyl or the like.

The above aralkyl group and aralkyl moiety of the aralkyloxy, aralkylthio and aralkylamino groups may be one containing 7 - 10 carbon atoms such as benzyl, phenethyl or the like.

The aromatic heterocyclic group having a chemical bond at a C atom may be a 5 or 6-membered aromatic heterocyclic one such as



35 The aromatic heterocyclic group having a chemical bond at a N atom may be a 5 or 6-membered N-containing one such as




45 Each of the above mentioned groups attached through C, O, S or N atom may further have one to four substituents such as nitro, amino, hydroxyl, cyano, carboxyl, sulfo, a halogen (fluorine, chlorine, bromine, etc.), an alkoxy containing 1 to 4 carbon atoms (methoxy, ethoxy, etc.), an alkylthio containing 1 to 4 carbon atom(s) (methylthio, ethylthio, etc.), phenylthio, benzylthio and the like.


50 Suitable examples of X include hydrogen atom, an C₁₋₁₀ alkyl, C₂₋₄ alkenyl, C₁₋₁₀ alkoxy, C₁₋₁₀ alkylthio, phenyl, halogen-substituted phenyl, aromatic heterocyclic group having a chemical bond at C or N atom or the like. Specific examples of these groups include the ones exemplified for B¹, B² and B³ in the above.

The symbol Y in the general formula (I) means an electron attractive group, such as cyano, carbamoyl, thiocarbamoyl or trichloromethyl group or the like. Cyano group is preferable as an example of Y.

Especially interesting compounds of this invention are ones represented by the following formula (I'):




wherein Q' is a group of the formula:




(one of B' and B'' is a C₁₋₆ alkyl, phenyl or substituted phenyl group and the other is a hydrogen atom), X' is a phenyl, halogen-substituted phenyl or aromatic heterocyclic group having a chemical bond at a C atom.

Another group of interesting compounds (I) is one represented by the following formula (I''):




wherein Q'' is




(B' is a phenyl or substituted phenyl group, B'' is a hydrogen atom or a C₁₋₆ alkyl group), and X'' is a phenyl, fluorine-substituted phenyl, thienyl or furyl group.

The C₁₋₆ alkyl group and substituted phenyl group exemplified in the above B', B'' and B³ are applicable to those in B', B', B'' and B'' of the formulas (I') and (I''). The halogen-substituted phenyl group for X' may be a phenyl group substituted by one to four halogens of fluorine, chlorine, bromine and so on. The fluorine-substituted phenyl group for X'' may be o-, m- or p-fluorophenyl, o,m- or o,p-difluorophenyl or 2,4,6-trifluorophenyl. The aromatic heterocyclic groups having a chemical bond at C atom mentioned in the symbol X are applicable to those of X'.

Preferable example of the symbols Q' and Q'' is



wherein n is 0, 1, 2, 3 or 4 and l is the same or different selected from a group comprising C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkylthio or halogen. The substituted phenyl groups mentioned in B' B'' and B³ are applicable to the group:



5

(n 0). X' and X'' is preferably 2-thienyl group, etc.

The compounds(I) of this invention contain an asymmetric carbon atom, and this invention include each isomer due to the asymmetric carbon atom and a mixture thereof.

10 The salt of the compounds (I) of this invention may be a salt formed by an alkali metal or alkaline earth metal such as sodium, magnesium, potassium, calcium, etc. with an acidic group (e.g., carboxy, etc.) contained as a substituent, or a salt formed by a mineral acid such as hydrochloric acid, phosphoric acid, sulfuric acid, etc. or an organic acid such as oxalic acid, acetic acid, benzoic acid, etc. with a basic group contained in the substituent(s) or condensed heterocycle.

15 The carboxylic acids (II) and (IV) having condensed heterocycle, which are used as the starting materials in this invention, or their salts can be prepared by a method similar to the known methods described in, for example, J. Org. Chem., Vol. 37, page 3107 (1972); J. Org. Chem., Vol. 36, page 2678 (1971); J. Org. Chem., Vol. 42, page 4197 (1977); J. Med. Chem., Vol. 17, page 645 (1974); J. Med. Chem., Vol. 20, page 386 (1977); J. Med. Chem., Vol. 15, page 982 (1972); J. Med. Chem., Vol. 28, page 876 (1985); Tetrahedron Lett., Vol. 21, page 2195 (1980); J. Chem., Soc., Perkin Trans. I. page 1159 (1987), and the like.

In more detail, some of the carboxylic acids (II) or (IV) or their salts can be prepared, for example, by reacting an aromatic heterocyclic aminocarboxylic acid, its reactive derivative or salt with a compound of the formula (VI) or (VII).

25 Especially, a compound (VIII) or its salt which is frequently used among novel compounds (IV) or their salts can be prepared by reacting a compound (V) or its salt with a compound (VI) or a compound (VII).

In the formulas (II), (IV), (V) and (VIII), Z denotes a leaving group and accordingly -COZ can denote -COOH or its reactive derivate. Thus, the compound (II) or its salt can be represented by a carboxylic acid of the formula:


30 Q-COOH (II')

wherein Q has the same meaning as defined above, or its reactive derivative, or its salt; the compound (IV) or its salt be represented by a carboxylic acid of the formula:

Q'-COOH (IV')

wherein Q' has the same meaning as defined above, or its reactive derivative, or its salt;

35 the compound (V) or its salt be represented by a carboxylic acid of the formula:



45 wherein the ring (A) has the same meaning as defined above or its reactive derivative, or its salt;

the compound (VIII) or its salt be represented by a carboxylic acid of the formula:

Q²-COOH (VIII')

wherein Q² has the same meaning as defined above, or its reactive derivative, or its salt, respectively.

50 Examples of the reactive derivatives at the carboxyl group in the aromatic heterocyclic amino carboxylic acid and carboxylic acids (II'), (IV'), (V') and (VIII') include the acid anhydrides, active amides, active esters or the like. Specific examples of such reactive derivatives are as follows:

1) Acid anhydrides may be mixed anhydrides with halogenic acids (e.g., hydrochloric acid or hydrobromic acid), mono-alkyl carbonates, aliphatic carboxylic acids (e.g., acetic acid, pivalic acid, valeric acid, isovaleric acid or trichloroacetic acid) or aromatic carboxylic acids (e.g., benzoic acid), or symmetric acid anhydrides.

2) Active amides may be amides with pyrazole, imidazole, 4-substituted imidazole, dimethylpyrazole or benzotriazole.

3) Active esters may be methyl ester, ethyl ester, methoxymethyl ester, propargyl ester, 4-nitrophenyl ester, 2,4-dinitrophenyl ester, trichlorophenyl ester, pentachlorophenyl ester or mesylphenyl ester, or other esters with 1-hydroxy-1H-2-pyrrolidone, N-hydroxysuccinimide or N-hydroxyphthalimide.

Such reactive derivatives at carboxyl group are suitably selected and used depending upon the kind of the used carboxylic acids.

Further, the above mentioned aromatic heterocyclic amino carboxylic acid and carboxylic acids (II'), (IV'), (V') and (VIII') may be used in their free form (i.e., carboxylic acid form), preferably in the presence of a condensing agent such as N,N'-dicyclohexylcarbodiimide, N-cyclohexyl-N'-morpholinoethylcarbodiimide, N-cyclohexyl-N'-(4-dimethylaminocyclohexyl)carbodiimide or N-ethyl-N'-(3-dimethylaminopropyl)-carbodiimide. In addition, the above carboxylic acids may be used as the salts with an alkali metal or alkaline earth metal.

The symbol W in the formula (VI) and (VII) denotes a halogen atom such as chlorine, bromine or fluorine. The ring \textcircled{A} in the formula (V) may be pyridine, pyridazine, pyrimidine or pyrazine ring, which may be substituted by a group as mentioned in R³,

Q² is preferably Q' or Q''.

This reaction can be carried out without solvent or in a suitable solvent and in the presence of a condensing agent such as a base, if necessary. The suitable solvents may be, alcohols such as ethanol, isopropyl alcohol, etc., aromatic hydrocarbons such as benzene, toluene, xylene, etc., halogenated hydrocarbons such as methylene chloride, chloroform, carbon tetrachloride, etc., ethers such as diethyl ether, dioxane, tetrahydrofuran, dimethoxyethane, etc., ketones such as acetone, methyl ethyl ketone, etc., nitriles such as acetonitrile, propionitrile, etc., amides such as dimethylformamide, dimethylacetamide, etc., esters such as methyl acetate, ethyl acetate, butyl acetate, etc., or a mixture thereof. If necessary, a mixed solvent of water and an aromatic hydrocarbon or halogenated hydrocarbon may be used. The solvent is usually used in 1 to 50 times (weight), preferably 5 to 10 times, to the carboxylic acids or their reactive derivatives or salts. The reaction may be accelerated by adding a base to the solvent. Suitable base may be, tertiary amines such as triethylamine, pyridine, 4-dimethylaminopyridine, DBU (1,8-diazabicyclo[5.4.0]-undec-7-ene), etc., alkali metal or alkaline earth metal hydroxide, carbonate or bicarbonate or alkali metal alcoholate such as sodium carbonate, potassium carbonate, sodium bicarbonate, sodium hydroxide, potassium hydroxide, sodium alcoholate, etc., or organic metal salt such as n-butyl lithium, etc. The base is usually used in 1 to 5 equivalents, preferably, 1 to 3 equivalents, to the carboxylic acids or their reactive derivatives or salts.

The compound of the formula (VI) or (VII) is used in an amount of 1.1 to 2.0 moles, to 1 mole of the carboxylic acid or its reactive derivative or salt in this reaction. This reaction may be carried out at room temperature (e.g., -10°C to 30°C) or at an elevated temperature (e.g., 30 to 100°C) for accelerating the reaction. The reaction time depends on the reaction temperature, etc., and it is usually 15 minutes to 24 hours, preferably 30 minutes to 10 hours.

Thus, the resulting compound (II) or (IV) can be isolated and purified as a free base by a known method such as chromatography on silica gel (Kiesel gel® 60 manufactured by Merck & Co., Inc., eluting solvent: chloroform, ethyl acetate, etc.), or isolated and purified as an acid addition salt with an inorganic acid such as hydrochloric acid, sulfuric acid, phosphoric acid, etc., or with an organic acid such as acetic acid, benzenesulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, citric acid, tartaric acid, oxalic acid, propionic acid, maleic acid, malic acid, malonic acid, fumaric acid, mandelic acid, ascorbic acid, etc. according to a conventional method by conventional means such as concentration, concentration under reduced pressure, extraction, phase transfer, crystallization, recrystallization or chromatography. In case where a carboxy group or the like is contained as a substituent in the compound, said compound can be derived to a salt with alkali metal or alkaline earth metal as exemplified before according to a conventional method, which can be further isolated and purified by conventional means as mentioned above.

The condensed heterocyclic carboxylic acid derivative (II) or (IV) or its salt prepared by the above reaction can also be derived to a nitro-substituted compound by a conventional nitration, or to a halogenated compound by using a halogenating agent such as N-bromosuccinimide (NBS), N-chlorosuccinimide (NCS), or the like.

The amines (III) and their salts (salts with the acids as mentioned in the above compounds (II) and (IV)) can be prepared by a known method or method similar thereto.

A compound (I) or its salt can be prepared by reacting a compound (II) or its salt with a compound (III) or its salt.

In more detail, a compound (I) or its salt can usually be prepared by reacting a compound (II) or its salt with a compound (III) or its salt without solvent or in a suitable solvent and in the presence of a suitable base or condensing agent. The suitable solvents may be, aromatic hydrocarbons such as benzene, toluene,

xylene, etc., halogenated hydrocarbons such as methylene chloride, chloroform, carbon tetrachloride, etc.,
 ethers such as diethyl ether, dioxane, tetrahydrofuran, etc., ketones such as acetone, methyl ethyl ketone,
 etc., nitriles such as acetonitrile, propionitrile, etc., amides such as dimethylformamide, dimethylacetamide,
 etc., esters such as methyl acetate, ethyl acetate, butyl acetate, etc., or a mixture thereof. If necessary, a
 5 mixture of water and an aromatic hydrocarbon or halogenated hydrocarbon may be used. The solvent is
 usually used in 1 to 50 times (weight), preferably 5 to 10 times, to the compound (II) or its salt. The reaction
 can be accelerated by adding a base to the solvent. The suitable bases may be, tertiary amines such as tri-
 ethylamine, pyridine, 4-dimethylaminopyridine, DBU (1,8-diazabicyclo[5,4,0]undec-7-ene), etc., alkali metal
 or alkaline earth metal hydroxides, carbonates or bicarbonates or alkali metal alcoholates such as sodium
 10 carbonate, potassium carbonate, sodium bicarbonate, sodium hydroxide, potassium hydroxide, sodium
 alcoholate etc., or organic metal salt such as n-butyl lithium, etc. Such base is usually used in 1 to 20
 equivalents, preferably 2 to 5 equivalents, to the compound (II) or its salt. The suitable condensing agents
 may be, thionyl chloride, phosphorus oxy-chloride, carbonyldiimidazole, N-methyl-2-bromo-pyridinium
 iodide, dicyclohexylimide, etc., or a mixture thereof. Such condensing agent is usually used in 1 to 10
 15 equivalents, preferably 2 to 5 equivalents, to the compound (II) or its salt.

In the reaction, the compound (II) or its salt is used in an amount of 1.1 to 1.5 moles to 1 mole of the
 compound (III) or its salt. The reaction may be carried out under cooling to at room temperature (-20 to
 30 °C), or at an elevated temperature such as about 30 to 100 °C to accelerate the reaction. Though the
 reaction time depends the reaction temperature, etc., it is usually 15 minutes to 15 hours, preferably about
 20 30 minutes to 8 hours.

Thus the resulting compound (I) can be isolated and purified as a free base by a known method such
 as chromatography on silica gel (Kiesel gel 60 manufactured by Merck & Co, Inc., eluting sol-
 vent:chloroform, ethyl acetate etc.), or isolated and purified as an acid addition salt with an inorganic acid
 such as hydrochloric acid, sulfuric acid, phosphoric acid, etc., or with an organic acid such as acetic acid,
 25 benzenesulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, citric acid, tartaric acid, oxalic acid,
 propionic acid, maleic acid, malic acid, malonic acid, fumaric acid, mandelic acid, ascorbic acid, etc.
 according to a conventional method, by conventional means as mentioned above. In case where a carboxy
 group or the like is contained as a substituent in the compound, said compound can be derived to a salt
 with alkali metal or alkaline earth metal as exemplified before according to a conventional method, and can
 30 be isolated and purified by conventional means as mentioned above.

Thus prepared compounds (I) of this invention or their salts possess an excellent effect for preventing
 and controlling various kinds of plant diseases caused by pathogenic fungi, especially downy mildew of
 vegetables such as cucumber, Chinese cabbage, onion, pulse, etc. and fruit trees such as vine, citrus,
 apple, etc., plant blight of tomato, potato, egg plant, green pepper, pumpkin, etc. Further, the compounds (I)
 35 of this invention and their salts maintain the stable fungicidal effect for a considerably long period of time
 after applying to plants (long-lasting effect), and are less in reduction of the efficacy due to little washing off
 by rain after application by spraying (rain-resistance effect). Thus, the compounds (I) and their salts exert
 sufficient effects even in the rainy season when downy mildew or plant blight occurs frequently. And further,
 the compounds (I) of this invention and their salts possess a safe and advantageous qualities as an
 40 agricultural fungicide, because damage on plants is low and toxicity to fish is also low.

The compound (I) of this invention or its salt can be used as a fungicide in a conventional form of
 agricultural chemicals. That is, a kind or two or more kinds of the compounds (I) of this invention and their
 salts may preferably be used in accordance with purpose in a form of emulsifiable concentrate, oily
 preparation, spray, wettable powder, powder, tablet, ointment, etc., which can be formed with a suitable
 45 carrier or carriers in a conventional manner, for example, by dissolved or dispersed in a proper liquid
 carrier, by mixed with a proper solid carrier or adsorbed on a proper solid carrier. If necessary, emulsifying
 agent, suspending agent, spreading agent, penetrating agent, moisturizing agent, adhesive, stabilizing
 agent, etc. may be added to the aforementioned preparations, which can be prepared by a conventional
 method.

50 The suitable rate of the compound (I) of this invention or its salt to the total fungicidal composition is
 about 1 to 80% by weight for emulsifiable concentrate or wettable powder, about 0.1 to 10% by weight for
 oily preparation and powder, and about 5 to 50% by weight for granules, though the concentration of the
 active ingredient may be varied in accordance with the purpose. The emulsifiable concentrates, wettable
 powders or the like is suitably diluted and extended (for example to 100 - 5000 times) with water or the like
 55 on the occasion of use, and then scattered.

Suitable liquid carrier (solvent) to be used may be, for example, water, alcohols (e.g. methanol, ethanol,
 n-propanol, isopropyl alcohol, ethylene glycol, etc.), ethers (e.g. dioxane, tetrahydrofuran, ethylene glycol
 monomethyl ether, diethylene glycol monomethyl ether, propylene glycol monomethyl ether, etc.), ketones

(e.g. acetone, methyl ethyl ketone, etc.), aliphatic hydrocarbons (e.g. kerosine, kerosene, fuel oil, machine oil, etc.), aromatic hydrocarbons (e.g. benzene, toluene, xylene, solvent naphtha, methylnaphthalene, etc.), halogenated hydrocarbons (e.g. methylene chloride, chloroform, carbon tetrachloride, etc.), acid amides (e.g. dimethylformamide, dimethylacetamide, etc.), esters (e.g. ethyl acetate, butyl acetate, fatty acid glycerol ester, etc.), nitriles (e.g. acetonitrile, propionitrile, etc.), or the like. These liquid carriers may be used individually or as an optional mixture thereof.

Suitable solid carrier (diluent or extender) may be vegetable powders (e.g. soybean flour, tobacco flour, wheat flour, sawdust, etc.), mineral powders (e.g. clays such as kaolin, bentonite, acid clay, talcs such as talc powder, pyrophyllite, silicas such as diatomaceous earth, mica powder, etc.), alumina, sulfur powder, active carbon, or the like. These solid carriers may be used individually or as an optional mixture thereof.

Suitable base for the ointment may be, for example, polyethylene glycol, pectin, polyalcohol esters of higher fatty acids such as glycerin mono-stearate, etc., cellulose derivatives such as methyl cellulose, etc., sodium alginate, bentonite, higher alcohols, polyalcohols such as glycerin, etc., vaseline, white petrolatum, liquid paraffin, lard, various kinds of vegetable oils, lanolin, dehydrated lanolin, hard oil, resins, or the like. These bases may be used individually or as an optional mixture thereof, or together with the surface active agent exemplified in the following.

Suitable surface active agent to be used, if necessary, as the emulsifying agent, spreading agent, penetrating agent, dispersing agent, etc. may be nonionic or anionic surface active agent such as soaps, polyoxyalkyl aryl esters (e.g. Nonal[®] manufactured by Takemoto Yushi K.K., Japan), alkyl sulfates (e.g. Emal 10[®], Eemal 40[®], manufactured by Kao-Atlas K.K., Japan), alkyl sulfonates (e.g. Neogen[®], Neogen T[®], manufactured by Dai-ichi Kogyo Seiyaku K.K., Japan : Neopellex[®], manufactured by Kao-Atlas K.K., Japan), polyethylene glycol ethers (e.g. Nonipol 85[®], Nonipol 100[®], Nonipol 160[®], manufactured by Sanyo Kasei K.K. Japan), polyalcohol esters (e.g. Tween 20[®], Tween 80[®], manufactured by Kao-Atlas K.K., Japan), or the like.

The fungicide of this invention can be applied at any time from seeds nursery plant to harvest. The fungicide of this invention can be used for controlling the outbreak of plant blight by previous administration and also for curing the plant blight by administration after the outbreak according to a conventional method.

The amount of the compound (I) of this invention or its salt to be used as an agricultural chemicals is variable in accordance with conditions such as growth stage and growth situation of the plant to be applied, kind of the plant blight, situation of the outbreak, administration time and method of the fungicide, etc. The compound (I) or its salt is usually used in an amount of about 3 to 300 g, preferably about 10 to 100 g per 10 are. The concentration of the active ingredient to be applied is preferably about 10 to 1000 ppm. The fungicide is usually applied by direct scattering, direct powdering or irrigating to the plant or by powdering to seeds. The amount, concentration and method of application may optionally be varied so far as the fungicide is used safely and effectively. The fungicide of this invention may be used, if necessary, in an optional combination with the other kind of fungicides (e.g. organic chlorine fungicide, organic phosphorus fungicide, benzimidazole-type fungicide, copper fungicide, organic sulfur fungicide, phenolic fungicide, triazole-type fungicide, pyrimidine-type fungicide, acrylic acid-type fungicide, sulfenamide-type fungicide, amino acid-type fungicide, antibiotic substance, etc.), insecticides (e.g. natural insecticide, carbamate-type insecticide, organic phosphorus insecticide, neaistoxin-type insecticide, synthesized pyrethroid, etc.), miticides, nematocides, herbicides, plant hormone drugs, plant growth regulators, stabilizing agents, synergists, attracting agents, repellents, perfumes, coloring agents, fertilizers, plant nutrients, various kinds of amino acids, low or high molecular phosphoric acids, or the like. Metal salts (e.g. copper chloride, copper sulfate, etc.) may also be added for the purpose of synergy.

The compounds (I) provided by this invention and their salts exhibit an excellent control or prevent effect against downy mildew and blight of vegetables and fruit trees. The compounds (I) or their salts are not washed away, possess an excellent rain-resistant property and accordingly exhibit the excellent control or prevent effect especially in a rainy season. The compounds (I) of this invention and their salts decrease the blight of vegetables and fruit trees, and can be used as an advantageous fungicide with no substantial damage to the crops.

Test 1 Prevention of blight of tomato

A compound of this invention was dissolved in dimethylformamide (final concentration : 1% by weight), xylene (final concentration : 0.02% by weight) and Tween 20[®] (final concentration 0.02% by weight) were added to the solution, and the mixture was diluted with water to a fixed concentration of the active ingredient. To this solution was added a spreading agent, Dyne[®] (manufactured by Takeda Chemical

Industries, Ltd., containing 20% (w/w) of polyoxyethylene nonyl phenyl ether and 12% of calcium lignin sulfonate) in a rate of 0.05% (w/w) (final concentration) to give a scattering solution. The solution was sprayed to young seedlings (about 4 weeks seedling) of tomato to an extent that the solution fell in drops. After air-drying, a suspension of zoospores of pathogen of tomato blight (concentration : about 10^5 /ml) was inoculated by spraying. After the inoculation, the plants were kept in a humid room at 17 °C for 5 days. The rate of area of the affected spots in the plant was surveyed, and the prevention value was shown in accordance with the following coefficients.

Prevention value 3 : affected area 0 - 5%

Prevention value 2 : affected area 6 - 15%

Prevention value 1 : affected area 16 - 30%

Prevention value 0 : affected area 31% or more.

The results are shown in Table 1.

Test 2 Prevention of downy mildew of cucumber.

A scattering solution containing a compound of this invention in a fixed concentration was prepared by the method described in the above Test 1, and the solution was sprayed to young seedlings (about 3 weeks seedling) of cucumber to an extent that the solution fell in drops. After air-drying, a suspension of zoospores of pathogen of downy mildew of cucumber (concentration : about 10^5 /ml) was inoculated by spraying. After the inoculation, the plants were kept in a humid room at 20 °C for one day and further in a humid room for 6 days. The rate of area of the affected spots in the plant was surveyed, and the prevention value was shown in accordance with the following coefficients.

Prevention value 3 : affected area 0 - 5%

Prevention value 2 : affected area 6 - 15%

Prevention value 1 : affected area 16 - 30%

Prevention value 0 : affected area 31% or more

The results are shown in Table 2.

30

Test 3 Prevention of downy mildew of vine.

A scattering solution containing a compound of this invention in a fixed concentration was prepared by the method described in the above Test 1, and the solution was sprayed to young trees of vine (about 6 weeks seedling) to an extent that the solution fell in drops. After air-drying, a suspension of zoospores of pathogen of downy mildew of vine (concentration : about 10^5 /ml) was inoculated by spraying. After inoculation, the plants were kept in a humid room at 18 °C for 10 days. The rate of area of the affected spots in the plant was surveyed, and the prevention value was shown in accordance with the following coefficients.

Prevention value 3 : affected area 0 - 5%

Prevention value 2 : affected area 6 - 15%

Prevention value 1 : affected area 16 - 30%

Prevention value 0 : affected area 31% or more

The results are shown in Table 3.

In the following Tables 1 - 3, the numbers in the column of the test compound mean the compound No. obtained in the Examples described below.

50

55

Table 1
Prevention of
blight of tomato

5

10

15

20

25

30

35

40

45

Compound No.	200ppm	Compound No.	200ppm
2-1	3	2-45	3
2-2	3	2-46	3
2-3	3	2-52	3
2-4	3	2-54	3
2-5	3	2-55	3
2-7	3	2-56	3
2-9	3	2-57	3
2-10	3	2-58	3
2-11	2	2-59	3
2-15	3	2-63	3
2-18	3	2-64	3
2-19	3	2-65	3
2-20	3	2-66	3
2-24	3	2-67	3
2-25	3	2-68	3
2-26	3	2-69	3
2-27	3	2-70	2
2-32	3	2-71	3
2-33	3	2-72	3
2-34	3	2-73	3
2-35	2	2-78	3
2-41	2		

50

55

Table 1 (continued)

	Compound No.	200ppm	Compound No.	200ppm
5	2-79	3	2-145	3
	2-80	3	2-146	3
10	2-81	1	2-147	3
	2-82	3	2-148	3
	2-83	3	2-149	3
15	2-92	2	2-150	3
	2-104	3	2-151	3
	2-109	3	2-152	3
20	2-114	3	2-153	3
	2-115	2	2-154	3
	2-119	3	2-155	3
25	2-120	3	2-156	3
	2-121	3	2-157	3
	2-122	3	2-158	3
	2-123	3	2-159	3
30	2-127	3	2-160	3
	2-128	3	2-161	3
	2-134	3	2-162	3
35	2-135	3	2-163	3
	2-136	3	2-164	3
	2-137	3	2-166	3
40	2-138	3	2-167	3
	2-139	3	2-168	3
	2-140	3	2-170	3
45	2-141	3	2-171	3
	2-142	3	2-173	3
	2-143	3	2-174	3
50	2-144	3	2-175	3

Table 1 (continued)

5	Compound No.	200ppm	Compound No.	200ppm
	2-176	3	2-190	3
10	2-177	3	2-194	3
	2-178	3	2-195	3
	2-179	3	2-196	3
15	2-180	3	2-197	3
	2-181	3	2-198	3
	2-182	3	2-200	3
20	2-183	3	2-201	3
	2-184	3	2-203	3
	2-185	3	2-204	3
	2-186	3	2-211	3
25	2-187	3	2-212	3
	2-188	3	2-214	3
	2-189	3	2-215	3
30				

35

40

45

50

55

Tabel 2
Prevention of downy
mildew of cucumber

5

10

15

20

25

30

35

40

45

50

Compound No.	200ppm	Compound No.	200ppm
2-1	3	2-41	3
2-2	3	2-42	3
2-3	3	2-45	3
2-4	3	2-46	3
2-5	3	2-48	3
2-7	3	2-52	3
2-9	3	2-54	3
2-10	3	2-55	3
2-11	3	2-56	3
2-15	3	2-57	3
2-18	3	2-58	3
2-19	3	2-59	3
2-20	3	2-63	3
2-24	3	2-64	3
2-25	3	2-65	3
2-26	3	2-66	3
2-27	3	2-67	3
2-28	3	2-68	3
2-29	3	2-69	3
2-32	3	2-70	3
2-33	3	2-71	3
2-34	3	2-72	3
2-35	2	2-73	3
2-37	3	2-78	3
2-40	1	2-79	3

55

Table 2 (continued)

	Compound No.	200ppm	Compound No.	200ppm
5	2-81	3	2-148	3
	2-82	3	2-149	3
10	2-83	3	2-150	3
	2-92	3	2-151	3
	2-104	3	2-152	2
15	2-109	3	2-153	3
	2-114	3	2-154	3
	2-115	3	2-155	3
20	2-119	3	2-156	3
	2-120	3	2-157	3
	2-121	3	2-158	3
	2-122	3	2-159	3
25	2-123	3	2-160	3
	2-127	3	2-161	3
	2-128	3	2-162	3
30	2-134	3	2-163	3
	2-135	3	2-164	3
	2-136	3	2-166	3
35	2-137	3	2-167	3
	2-138	3	2-168	3
	2-139	3	2-170	3
40	2-140	3	2-171	3
	2-141	3	2-173	3
	2-142	3	2-174	3
	2-143	3	2-175	3
45	2-144	3	2-176	3
	2-145	3	2-177	3
	2-146	3	2-178	3
50	2-147	3	2-179	3

Table 2 (continued)

Compound No.	200ppm	Compound No.	200ppm
2-180	3	2-195	3
2-181	3	2-196	3
2-182	3	2-197	3
2-183	3	2-200	3
2-184	3	2-201	3
2-185	3	2-203	3
2-186	3	2-204	3
2-187	3	2-211	3
2-188	3	2-212	3
2-189	3	2-214	3
2-190	3	2-215	3
2-194	3		

Table 3
Prevention of downy
mildew of vine

5

10

15

20

25

30

35

40

45

50

55

Compound No.	200ppm	Compound No.	200ppm
2-1	3	2-35	3
2-2	3	2-36	3
2-4	3	2-37	3
2-5	3	2-41	3
2-7	3	2-42	1
2-9	2	2-46	2
2-10	2	2-48	3
2-11	3	2-49	3
2-15	3	2-50	2
2-18	2	2-54	2
2-19	3	2-55	3
2-20	2	2-56	3
2-24	3	2-57	3
2-25	3	2-58	3
2-26	3	2-59	3
2-27	3	2-63	2
2-34	3	2-64	2

Table 3 (continued)

	Compound No.	200ppm	Compound No.	200ppm
5	2-65	3	2-143	3
	2-66	3	2-144	3
10	2-67	3	2-145	3
	2-68	2	2-146	3
	2-69	3	2-147	3
15	2-70	3	2-148	3
	2-71	2	2-149	3
	2-72	2	2-150	3
20	2-73	3	2-151	3
	2-78	2	2-152	3
	2-79	3	2-153	3
25	2-82	3	2-154	3
	2-83	3	2-155	3
	2-92	3	2-156	3
	2-104	1	2-157	3
30	2-109	3	2-158	3
	2-119	3	2-159	3
	2-120	3	2-160	3
35	2-121	3	2-161	3
	2-122	3	2-162	3
	2-123	3	2-163	3
40	2-127	3	2-164	2
	2-128	3	2-165	2
	2-134	2	2-166	3
	2-135	3	2-167	3
45	2-140	3	2-168	3
	2-141	3	2-170	3
50	2-142	3	2-171	3

It is shown by the above test results that the compounds (I) of this invention and their salts possess an excellent effect for preventing the downy mildew and blight of vegetables and fruit trees.

55

(f) Examples

This invention is explained in more detail by the following Examples. However, this invention shall not be limited to these Examples.

In the following Examples, elution in the column chromatography was carried out under the observation of TLC (Thin Layer Chromatography). The observation of TLC was conducted by using Kesel gel 60F 254 (Art*5715) manufactured by Merck & Co. as a TLC plate, the same solvent as the one used as an eluent of column chromatography as a developing solvent, and UV detector as a detecting method. The silica gel filled in a column was Kesel gel 60 (70 - 230 mesh, Art. 7734) manufactured by Merck & Co. The NMR spectrum means proton NMR (¹HNMR), and tetramethylsilane was used as an internal or external standard. The NMR spectrum was measured by VARIAN EM 390 (90 MHz) type spectrometer in case special description is not given, and each δ value was shown by ppm. Numerical value in the parentheses means mixing rate by volume of each solvent used in a mixed solvent as an eluent.

Each abridgment used in the following Examples has the following meanings.

s : singlet, d : doublet, m : multiplet, br : broad, J : coupling constant, Hz : Hertz, CDCl₃ : heavy chloroform, DMSO-d₆ : heavy dimethyl sulfoxide, % (except for yield) : w/w %.

The room temperature means about 15 to 25 °C.

Example 1

20

Synthesis of methyl imidazo[1,2-a]pyridine-8-carboxylate (Compound No. 1 - 1)

47% Hydrogen bromide (2.5ml, 14.4m moles) was added to diethoxybromoethane (2.0ml, 13.2m moles), and the mixture was stirred at 50 °C for 2 hours. The reaction mixture was cooled to room temperature, and ethanol (7.0ml) and sodium bicarbonate (1.0g, 11.9m moles) were added thereto. The mixture was stirred, and insoluble substance was filtered off. To the filtrate were added methyl 2-aminonicotinate (1.0g, 6.6m moles), sodium bicarbonate (2.0g, 13.8m moles) and ethanol (7.0ml), and the mixture was refluxed under heating for 4 hours. The reaction mixture was cooled to room temperature, and saturated aqueous solution of sodium bicarbonate was added thereto. The mixture was extracted with dichloromethane (100ml x 3), and the extract was washed with water, dried over anhydrous magnesium sulfate (MgSO₄) and concentrated under reduced pressure. The concentrate was purified by column chromatography on silica gel (eluent : chloroform and then chloroform/methanol = 9/1) to give the object compound (0.6g, yield 55%) as yellow crystals. m.p. 67 - 69 °C.

35

Example 2

Synthesis of methyl 2-methylimidazo[1,2-a]pyridine-8-carboxylate (Compound No. 1 - 3)

40

Bromoacetone (6.5g, 42.7m moles) and methyl 2-aminonicotinate (4.8g, 31.5m moles) were added to ethanol (50ml), and the mixture was refluxed under heating for 17 hours. The reaction mixture was cooled to room temperature, and the solvent was distilled off under reduced pressure. Saturated aqueous solution of sodium bicarbonate (50ml) was added to the residue, and the mixture was extracted with chloroform (100ml x 3). The extract was washed with water, dried over MgSO₄ and concentrated under reduced pressure. The concentrate was purified by column chromatography on silica gel (eluent:chloroform and then chloroform/methanol = 9/1) to give the object compound (4.0g, yield 85%) as an oily substance.

Example 3

Synthesis of hydrogen bromide salt of ethyl 2-phenyl-imidazo[1,2-a]pyridine-8-carboxylate (Compound No. 1-25).

55

Phenacyl bromide (11.0g, 55.3m moles) and ethyl 2-aminonicotinate (8.68g, 52.2m moles) were added to methyl ethyl ketone (100 ml), and the mixture was refluxed under heating for 5.5 hours. The reaction mixture was left to stand at room temperature overnight, and the precipitating crystals were collected by

filtration to give the object compound (16.3g, yield 89.96%) as crystals. m.p. 174 - 176 °C.

Example 4

Synthesis of methyl 3-chloro-2-methylimidazo[1,2-a]pyridine-8-carboxylate (Compound No. 1-15).

Methyl 2-methylimidazo[1,2-a]pyridine-8-carboxylate (5.3g, 27.9m moles) was dissolved in chloroform (30ml), and N-chlorosuccinimide (3.7g, 27.9m moles) was added to the solution and reacted at room temperature for 40 minutes. To the reaction mixture was added 10% aqueous solution of sodium carbonate (80ml), and the mixture was stirred for 30 minutes. The organic layer was separated from the reaction mixture, and the aqueous layer was extracted with chloroform (10ml x 3). The extracts were combined, washed with water, dried over MgSO₄ and concentrated under reduced pressure. The concentrate was purified by column chromatography on silica gel (eluent:chloroform) to give the object compound (3.6g, yield 57%) as an oily substance.

Example 5

Synthesis of methyl 3-dimethylaminomethyl-2-methylimidazo[1,2-a]pyridine-8-carboxylate (Compound No. 1-17).

To acetonitrile (10ml) were added 37% formaldehyde (0.3ml) and acetic acid (0.4ml), and 50% aqueous solution of dimethylamine (0.3ml) was added slowly to the mixture at 0 °C with stirring. Methyl 2-methylimidazo[1,2-a]pyridine-8-carboxylate (1.0g, 3.7m moles) was added to the mixture and reacted at 50 °C for 2 hours and then at room temperature for 2.5 hours. The reaction mixture was concentrated under reduced pressure and neutralized with saturated aqueous solution of NaHCO₃. The solution was extracted with dichloromethane, and the extract was washed with water, dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the object compound (0.48g, Yield 52%) as crystals. m.p. 123 - 124 °C.

Example 6

Synthesis of 2-methylimidazo[1,2-a]pyridine-8-carboxylic acid (Compound No. 1-4)

Methyl 2-methylimidazo[1,2-a]pyridine-8-carboxylate (4g, 21m moles) was dissolved in a mixture of ethanol (45ml) and water (20ml), and sodium hydroxide (2.5g, 63m moles) was added thereto and refluxed under heating for 30 minutes. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. Water (40ml) was added to the concentrate, and the mixture was adjusted to pH 4 with conc. hydrochloric acid. The precipitating crystals were collected by filtration to give the object compound (2.3g, yield 64%).

Example 7

Synthesis of 2-phenylimidazo[1,2-a]pyridine-8-carboxylic acid (Compound No. 1-26)

Hydrogen bromide salt of ethyl 2-phenylimidazo [1,2-a] pyridine-8-carboxylate (8.4g, 24.2m moles) was added to 20% aqueous solution of NaOH (200ml) and ethanol (100ml), and the mixture was refluxed under heating for 1 hour. The reaction mixture was cooled to room temperature, and alcohol was distilled off under reduced pressure. The concentrate was adjusted to pH 4 with conc. hydrochloric acid, and the precipitating crystals were collected by filtration to give the object compound (5.67g, yield 98.4%) as crystals. m.p. 226 °C.

Example 8

Synthesis of 2-chloromethylimidazo[1,2-a]pyridine-8-carboxylic acid (Compound No. 1-90)

5 Ethyl 2-chloromethylimidazo[1,2-a]pyridine-8-carboxylate (8.4g, 35.2m moles) was added to conc. hydrochloric acid (100ml), and the mixture was refluxed under heating for 5 hours. The reaction mixture was cooled to room temperature and adjusted to pH 4 with saturated aqueous solution of sodium bicarbonate. The precipitating crystals were collected by filtration to give the object compound (5.67g, yield 76.9%) as
 10 crystal. m.p. 250 ° C (decomp.).

Example 9

Synthesis of 3-nitro-2-(4-nitrophenyl)-imidazo[1,2-a]pyridine-8-carboxylic acid (Compound No. 1-96)

15 Ethyl 2-phenylimidazo[1,2-a]pyridine-8-carboxylate (2.9, 10m mol) was dissolved in conc. sulfuric acid (5ml), and to the solution was slowly added 70% nitric acid (1.3ml) at 10 ° C. After addition, the mixture was stirred at room temperature for 30 minutes, poured into ice water and adjusted to pH 7 by adding 20% sodium hydroxide. The precipitated crystals were collected by filtration, which were ethyl ester of the title compound (3.6g, yield 99.2%). A solution of the crystals in conc. hydrochloric acid (35ml) was refluxed for 1.5 hours and cooled to room temperature. The precipitated crystals were collected by filtration and dried to
 25 give the object compound (2.9g, yield 87.3%). m.p. >300 ° C.

Example 10

30 Synthesis of 3-nitroimidazo[1,2-a]pyridine-8-carboxylic acid (Compound No. 1 - 125)

Ethyl 2-ethoxycarbonylimidazo[1,2-a]pyridine-8-carboxylate (3.8g, 14.5m mol) was dissolved in conc. sulfuric acid (10ml), and to the solution was slowly added 70% nitric acid (1.5ml) at 10 ° C. The mixture was stirred at room temperature for 30 minutes, poured into ice water and adjusted to pH 7 by adding 20%
 35 sodium hydroxide. The precipitated crystals were filtered to obtain ethyl 2-ethoxycarbonyl-3-nitro-imidazo[1,2-a]pyridine-8-carboxylate (2.4g, yield 53.8%) as crystals of m.p. 139 - 140 ° C. A solution of the crystals in conc. hydrochloric acid (35ml) was refluxed for 1.5 hours and cooled to room temperature. The precipitated crystals were collected by filtration and dried to give the object compound (1.2g, yield 74.3%) of m.p. > 300 ° C.

Example 11

45 Synthesis of ethyl 3-formyl-2-phenyl-imidazo[1,2-a]pyridine-8-carboxylate (Compound No. 1 - 119)

To a solution of ethyl 2-phenyl-imidazo[1,2-a]pyridine-8-carboxylate hydrogen bromide (14.7g, 4m mol) in DMF (8ml) was dropwise added phosphorus oxychloride (2ml) keeping the inner temperature to below 15 ° C. Then, the mixture was allowed to react at room temperature for 30 minutes and at 70 ° C for 2 hours.
 50 After completion of the reaction, the reaction mixture was cooled, poured into ice water and adjusted to pH 7 by adding 20% sodium hydroxide. The precipitated crystals were collected by filtration and recrystallized from ethanol to obtain the object compound (1.0g, yield 85.5%) as colorless crystals. m.p. 139 ° C.

55 Example 12

Synthesis of ethyl 3-cyano-2-phenyl-imidazo[1,2-a]pyridine-8-carboxylate (Compound No. 1 - 121)

Ethyl 2-phenyl-imidazo[1,2-a]pyridine-8-carboxylate hydrogen bromide (1.96g, 5.35m mol), and triethylamine (0.55g, 5.44m mol) were added to acetonitrile (20ml). To this solution was dropwise added a solution of chlorosulfonylisocyanate (ClSO₂NCO) (0.8ml, 9.19m mol) in acetonitrile (5ml) at an inner temperature of 0 - 20 °C. Then, the mixture was allowed to react at room temperature for an hour. After completion of the reaction, the mixture was concentrated under reduced pressure. The resulting concentrate to which water was added was extracted with dichloromethane, and the extract was washed with water, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (eluent : chloroform) to give the object compound (1.06g, yield 67.9%) as crystals. m.p. 87 - 89 °C.

Example 13

15 Synthesis of ethyl 2-ethoxycarbonyl-imidazo[1,2-a]pyridine-8-carboxylate (Compound No. 1 - 123)

A mixture of ethyl bromopyruvate (2.3g, 10.2m mol) and ethyl 2-aminonicotinate (1.7g, 10m mol) in methyl ethyl ketone (17ml) was refluxed for 5 hours. After completion of the reaction, the mixture was cooled to room temperature and distilled under reduced pressure to remove the solvent. The residue to which saturated sodium hydrogen carbonate aqueous solution (50ml) was added was extracted with chloroform (100ml x 3). The extract was washed with water, dried over MgSO₄ and concentrated under reduced pressure. The concentrate was purified by silica gel column chromatography (eluent : ethyl acetate) to give the object compound (0.7g, yield 26.7%) as crystals. m.p. 97 °C.

Example 14

30 Synthesis of ethyl 2-methyl-3-sulfoimidazo[1,2-a]imidazo[1,2-a]pyridine-8-carboxylate (Compound No. 1 -127)

To a solution of ethyl 2-methyl-imidazo[1,2-a]pyridine-8-carboxylate (1.2g, 5.9m mol) in chloroform (15ml) was added chlorosulfonic acid (0.6ml). The mixture was refluxed for 3 hours, and then concentrated under reduced pressure. The precipitated crystals were collected by filtration, washed sufficiently with water and dried to give the object compound (1.2g, yield 71.4%) as crystals. m.p. 247 - 250 °C (decomp.).

Example 15

40 Synthesis of ethyl 2-methyl-3-N-methylsulfamoylimidazo[1,2-a]pyridine-8-carboxylate (Compound No. 1 -129)

Ethyl 2-methyl-3-sulfo-imidazo[1,2-a]pyridine-8-carboxylate (1.7g) and tri-n-propylamine (2.6g) were added to acetonitrile (17ml). Phosphorus oxychloride (1.1ml) was added to the mixture, keeping the inner temperature to 50 - 60 °C. Then, the mixture was allowed to react at the same temperature for an hour. After completion of the reaction, the mixture was concentrated under reduced pressure, and water was added to the residue. The precipitated crystals were collected by filtration, washed with water and dried to obtain ethyl 2-methyl-3-chlorosulfonyl-imidazo[1,2-a]pyridine-8-carboxylate (1.2g, yield 66.3%) as crystals of m.p. 182 - 183 °C.

The crystals (1.2g) was dissolved in acetonitrile (12ml), to which a solution of 40% methylamine aqueous solution (0.75g) in acetonitrile (3ml) was dropwise added at an inner temperature of 0 - 10 °C. Then, the mixture was allowed to react at room temperature for an hour. After completion of the reaction, the mixture was concentrated under reduced pressure. The concentrate to which water was added was adjusted to pH 7 with dilute hydrochloric acid. The precipitated crystals was collected by filtration, washed with water and dried to obtain the object compound (1.1g, yield 93.2%) as crystals. m.p. 184 - 185 °C.

Example 16

Synthesis of 2-chloro-imidazo[1,2-a]pyridine-8-carboxylic acid (Compound No. 1 - 135)

5 A mixture of diethyl bromomalonate (26ml) and ethyl 2-aminonicotinate (13.3g) was allowed to react at 80 - 90 ° C for 6 hours under nitrogen atmosphere. After completion of the reaction, the mixture was cooled to room temperature, and acetone (100ml) was added thereto. The precipitated crystals were collected by filtration, affording 3,8-diethoxycarbonyl-2-hydroxy-imidazo[1,2-a]pyridine hydrobromide (9.98g, yield 34.8%).

10 A mixture of the crystals (6.6g) in phosphorus oxychloride (30ml) was reacted at 160 ° C for 2 hours in a pressure reaction vessel. After completion of the reaction, excess phosphorus oxychloride was removed under reduced pressure. Ethanol was added to the residue, and the mixture was concentrated under reduced pressure. The concentrate was purified by silica gel column chromatography (eluent : chloroform) to obtain 2-chloro-3,8-diethoxycarbonyl-imidazo-[1,2-a]pyridine (Compound No. 1 - 133) (2.2g, yield 40.3%) as crystals of m.p. 105 - 106 ° C.

15 The crystals (0.9g) were dissolved in ethanol (10ml), and 10% sodium hydroxide (5ml) was added thereto. The mixture was allowed to react at room temperature for an hour and then adjusted to pH 4 with conc. hydrochloric acid. The precipitated crystals were collected by filtration, washed with water and dried to obtain 2-chloro-imidazo[1,2-a]pyridine-3,8-dicarboxylic acid (0.73g, yield 100%) as crystals of m.p. 210 - 212 ° C (decomp.). Then, a mixture of the crystals (0.73g) in conc. hydrochloric acid (5ml) was refluxed for 2 hours. The reaction solution was adjusted to pH 4 with saturated sodium hydrogen carbonate aqueous solution, to yield crystals of the object compound (0.5g, yield 83.9%). m.p. 237 ° C.

25

Example 17

Synthesis of α -(imidazo[1,2-a]pyridin-8-ylcarbonylamino)-(2-furyl)acetonitrile (Compound No. 2-1)

30 α -(2-Furyl)- α -aminoacetonitrile (0.7g, 5.5m mols) was dissolved in acetonitrile (20ml), and imidazo[1,2-a]pyridine-8-carboxylic acid chloride (1.0g, 5.5m moles) was added thereto with stirring and reacted at room temperature for 2 hours. After completion of the reaction, the solvent was removed from the reaction mixture under reduced pressure. To the residue were added water (20ml), saturated aqueous solution of sodium bicarbonate (50ml) and chloroform (50ml), and the mixture was stirred. The organic layer was separated, dried over anhydrous magnesium sulfate and concentrated. The concentrate was purified by column chromatography on silica gel (eluent:ethyl acetate/n-hexane = 2/1) to give the object compound (0.16g, yield 11%) as crystals. m.p. 149 - 151 ° C.

40

Example 18

Synthesis of α -(imidazo[1,2-a]pyridin-5-ylcarbonylamino)-(2-furyl)acetonitrile (Compound No.2-134)

45 α -(2-Furyl)- α -aminoacetonitrile (0.7g, 5.5m moles) was dissolved in acetonitrile (20ml), and imidazo[1,2-a]pyridine-5-carboxylic acid chloride (1.0g, 5.5m moles) was added thereto and reacted at room temperature for 2 hours. After completion of the reaction, the solvent was removed from the reaction mixture. To the residue were added water (20ml), saturated aqueous solution of sodium bicarbonate (50ml) and chloroform (50ml), and the mixture was stirred. The organic layer was separated, dried over anhydrous magnesium sulfate and concentrated. The concentrate was purified by column chromatography on silica gel (eluent : methanol/chloroform = 1/9) to give the object compound (0.9g, yield 64%) as amorphous solid.

55 Exmple 19

Synthesis of α -(2-phenyl-imidazo[1,2-a]pyridin-8-ylcarbonylamino)-(2-furyl)acetonitrile (Compound No. 2 -

24)

2-Phenyl-imidazo[1,2-a]pyridine-8-carboxylic acid (1.5g, 5.5m moles) was added to dried tetrahydrofuran (100ml), and carbonyldiimidazole (1.5g, 5.5m moles) was added slowly thereto with stirring at room temperature in an atmosphere of nitrogen gas. The mixture was stirred at room temperature for 8 hours, and α -(2-furyl)- α -aminoacetonitrile (0.7g, 5.5m moles) was added to the mixture and reacted at room temperature for 5 hours. The solvent was removed from the reaction mixture under reduced pressure, and water (20ml) and ethyl acetate (50ml) were added to the residue and stirred. The organic layer was separated, dried over anhydrous magnesium sulfate and then concentrated. The concentrate was purified by column chromatography on silica gel (eluent : ethyl acetate/n-hexane = 1/1) to give the object compound (0.9g, yield 64%) as crystals. m.p. 197 - 199 ° C.

Example 20

Synthesis of α -(3-chloro-imidazo[1,2-a]pyridin-8-ylcarbonylamino)-(2-furyl)acetonitrile [Compound No. 2 - 10]

3-Chloro-imidazo[1,2-a]pyridine-8-carboxylic acid (1.8g, 9.2m moles) was added to thionyl chloride (20ml), and the mixture was refluxed under heating and stirring for 30 minutes and then concentrated under reduced pressure. The resultant crude acid chloride and α -(2-furyl)- α -aminoacetonitrile (1.1g, 8.5m moles) were added to acetonitrile (50ml) and reacted at room temperature for 1 hour with stirring. The solvent was removed from the reaction mixture under reduced pressure, and water (20ml), saturated aqueous solution of sodium bicarbonate (50ml) and chloroform (50ml) were added to the residue and stirred. The organic layer was separated, dried over anhydrous magnesium sulfate and then concentrated. The concentrate was purified by column chromatography or silica gel (eluent : ethyl acetate/n-hexane = 1/2) to give the object compound (0.6g, yield 22%) as crystals. m.p. 142 - 143 ° C.

Example 21

Synthesis of α -(2-phenyl-imidazo[1,2-a]pyridin-8-ylcarbonylamino)-(3-chlorophenyl)acetonitrile (Compound No. 2 - 35)

2-Phenyl-imidazo[1,2-a]pyridine-8-carboxylic acid (1.0g, 4.2m moles), α -(3-chlorophenyl)-aminoacetonitrile (0.77g, 4.6m moles) and NaHCO₃ (1.1g, 13.1m moles) were added to acetonitrile (10ml). Phosphorus oxychloride (0.7ml, 7.51m moles, dissolved in 5ml of acetonitrile) was added slowly to the mixture with stirring under ice-cooling. The mixture was reacted at room temperature for 10 hours, and the solvent was removed from the reaction mixture under reduced pressure. Water (50ml) was added to the residue and the mixture was adjusted to pH 7 with saturated aqueous solution of sodium bicarbonate and then extracted with dichloromethane/ethyl acetate (10/1) (100ml x 2). The extract was dried over anhydrous magnesium sulfate and concentrated. Acetonitrile (5ml) was added to the concentrate, and the precipitating crystals were collected by filtration to give the object compound (0.44g, yield 27.2%) as crystals. m.p. 210 - 211 ° C.

Example 22

Synthesis of α -(3-dimethylaminomethyl-2-phenylimidazo[1,2-a]pyridin-8-ylcarbonylamino)-(3-fluorophenyl)-acetonitrile (Compound No. 2 - 79)

To acetonitrile (10ml) were added 37% formaldehyde (0.3ml) and acetic acid (0.4ml), and 50% aqueous solution of dimethylamine (0.3ml) was added slowly thereto at 0 ° C with stirring. To the mixture was added α -(2-phenyl-imidazo[1,2-a]pyridin-8-ylcarbonylamino)-(3-fluorophenyl)acetonitrile (1.0g, 2.7m moles), and the mixture was reacted at 50 ° C for 2 hours and further stirred at room temperature for 2.5 hours. The reaction

mixture was concentrated under reduced pressure, and the concentrate was neutralized with saturated aqueous solution of NaHCO_3 . The solution was extracted with dichloromethane, and the extract was washed with water, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The concentrate was purified by column chromatography or silica gel (eluent : chloroform) to give the object compound (0.47g, yield 40.8%) as crystals. m.p. $123-124^\circ\text{C}$.

Example 23

10

Synthesis of α -(3-methylsulfinylmethyl-imidazo[1,2-a]pyridin-8-ylcarbonylamino)-(2-furyl)acetonitrile (Compound No. 2 - 122)

α -(2-Methylthiomethyl-imidazo[1,2-a]pyridin-8-ylcarbonylamino)-(2-furyl)acetonitrile (0.33g, 1m mole) was added to chloroform (10ml), and m-chloroperbenzoic acid (0.25g, 1.1m moles) was added to the mixture at internal temperature of 5°C . The mixture was stirred at room temperature for 2.5 hours, and the reaction mixture was treated with saturated aqueous solution of NaHCO_3 . The chloroform layer was separated, washed with water, dried over anhydrous sodium sulfate and then concentrated under reduced pressure. The concentrate was purified by column chromatography or silica gel (eluent : ethyl acetate) to give the object compound (0.1g, yield 30.3%) as crystals. m.p. $214-216^\circ\text{C}$.

Example 24


25

Synthesis of α -(2-(trifluoromethyl-imidazo[1,2-a]pyridin-8-ylcarbonylamino)-(3-fluorophenyl)acetamide (Compound No. 2 - 169)

A mixture of α -(2-(trifluoromethyl-imidazo[1,2-a]pyridin-8-ylcarbonylamino)-(3-fluorophenyl)acetonitrile (1.26g) and chlorosulfonic acid (0.5ml) in chloroform (13ml) was refluxed for 1.5 hours. The reaction solution was concentrated under reduced pressure, and water was added to the residue. The precipitated crystals were collected by filtration and recrystallized from ethanol to obtain the object compound (0.45g, yield 34.1%) as crystals. m.p. $118-120^\circ\text{C}$

The compounds (II) obtained in a similar manner to those of Examples 1 - 16 are shown in Table 4, their melting points and NMR data are shown in Table 5, the compounds (I) obtained in a similar manner to those of Examples 17 - 24 are shown in Table 6, and their melting points and NMR data are shown in Table 7, respectively.

40



45

50

55

Table 4

	Compound No.	R ¹	R ²	R ³	R ⁴	R ⁵
5	1-1	H	H	H	H	Me
	1-2	H	H	H	H	H
	1-3	Me	H	H	H	Me
	1-4	Me	H	H	H	H
10	1-5	Et	H	H	H	Me
	1-6	Et	H	H	H	H
	1-7	nPr	H	H	H	H
	1-8	iPr	H	H	H	Me
15	1-9	iPr	H	H	H	H
	1-10	nBu	H	H	H	H
	1-11	tBu	H	H	H	Me
	1-12	tBu	H	H	H	H
20	1-13	H	Cl	H	H	Et
	1-14	H	Cl	H	H	H
	1-15	Me	Cl	H	H	Me
	1-16	Me	Cl	H	H	H
25	1-17	Me	CH ₂ NMe ₂	H	H	Me
	1-18	Me	CH ₂ NMe ₂	H	H	H
	1-19	Me	Me	H	H	H
	1-20	Me	CH ₂ CH ₂ CN	H	H	H
30	1-21	Me	CHO	H	H	H
	1-22	Me	NO ₂	H	H	H
	1-23	Me	CH=CHMe ₂	H	H	H
	1-24	C ₆ H ₅	H	H	H	Me
35	1-25	C ₆ H ₅	H	H	H	Et
	1-26	C ₆ H ₅	H	H	H	H
	1-27	2-MeC ₆ H ₄	H	H	H	Me
40						
45						
50						
55						

Table 4 (continued)

	Compound No.	R ¹	R ²	R ³	R ⁴	R ⁵
5	1-28	2-MeC ₆ H ₄	H	H	H	H
	1-29	2-MeC ₆ H ₄	H	H	H	Et
	1-30	3-MeC ₆ H ₄	H	H	H	Me
10	1-31	3-MeC ₆ H ₄	H	H	H	H
	1-32	4-MeC ₆ H ₄	H	H	H	Me
	1-33	4-MeC ₆ H ₄	H	H	H	H
15	1-34	2,5-Me ₂ C ₆ H ₃	H	H	H	H
	1-35	2,4,6-Me ₃ C ₆ H ₂	H	H	H	H
	1-36	2-MeOC ₆ H ₄	H	H	H	Me
20	1-37	2-MeOC ₆ H ₄	H	H	H	H
	1-38	3-MeOC ₆ H ₄	H	H	H	Me
	1-39	3-MeOC ₆ H ₄	H	H	H	H
25	1-40	4-MeOC ₆ H ₄	H	H	H	Me
	1-41	4-MeOC ₆ H ₄	H	H	H	H
	1-42	3,4-(MeO) ₂ C ₆ H ₃	H	H	H	Et
30	1-43	3,4-(MeO) ₂ C ₆ H ₃	H	H	H	H
	1-44	2-ClC ₆ H ₄	H	H	H	Me
	1-45	2-ClC ₆ H ₄	H	H	H	H
35	1-46	3-ClC ₆ H ₄	H	H	H	Me
	1-47	3-ClC ₆ H ₄	H	H	H	H
	1-48	4-ClC ₆ H ₄	H	H	H	Me
40	1-49	4-ClC ₆ H ₄	H	H	H	H
	1-50	4-BrC ₆ H ₄	H	H	H	Me
	1-51	4-BrC ₆ H ₄	H	H	H	H
45	1-52	4-NO ₂ C ₆ H ₄	H	H	H	Me
	1-53	4-NO ₂ C ₆ H ₄	H	H	H	H
	1-54	2-FC ₆ H ₄	H	H	H	H

Table 4 (continued)

Compound No.	R ¹	R ²	R ³	R ⁴	R ⁵
1-55	2-F, 4-MeC ₆ H ₃	H	H	H	H
1-56	2-Me, 4-MeSC ₆ H ₃	H	H	H	H
1-57	2,4,6-Cl ₃ C ₆ H ₂	H	H	H	H
1-58	C ₆ H ₅	CH ₂ NMe ₂	H	H	Me
1-59	C ₆ H ₅	CH ₂ NMe ₂	H	H	H
1-60	C ₆ H ₅	Cl	H	H	Me
1-61	C ₆ H ₅	Cl	H	H	H
1-62	C ₆ H ₅	Me	H	H	H
1-63	C ₆ H ₅	C ₆ H ₅	H	H	Me
1-64	C ₆ H ₅	C ₆ H ₅	H	H	H
1-65	C ₆ H ₅	CHO	H	H	Et
1-66	C ₆ H ₅	NO ₂	H	H	H
1-67	C ₆ H ₅	CN	H	H	H
1-68	C ₆ H ₅	CH ₂ CH ₂ CN	H	H	H
1-69	C ₆ H ₅	CH=CHMe ₂	H	H	H
1-70	C ₆ H ₅ CH ₂	H	H	H	H
1-71	CF ₃	H	H	H	Et
1-72	CF ₃	H	H	H	H
1-73	Cl	H	H	H	Et
1-74	Cl	Cl	H	H	Et
1-75	OMe	H	H	H	Et
1-76	OMe	H	H	H	H
1-77	SMc	H	H	H	H
1-78	H	OMe	H	H	H
1-79	2-thienyl	H	H	H	Et
1-80	2-thienyl	H	H	H	H
1-81	C ₆ H ₅	H	5-Mc	H	Me

Table 4 (continued)

	Compound No.	R ¹	R ²	R ³	R ⁴	R ⁵
5	1-82	C ₆ H ₅	H	5-Me	H	H
	1-83	C ₆ H ₅	H	5-Me	7-Me	Et
	1-84	C ₆ H ₅	H	5-Me	7-Me	H
10	1-85	C ₆ H ₅ OCH ₂	H	H	H	Me
	1-86	C ₆ H ₅ OCH ₂	H	H	H	H
	1-87	C ₆ H ₅ SCH ₂	H	H	H	Et
15	1-88	C ₆ H ₅ SCH ₂	H	H	H	H
	1-89	CH ₂ Cl	H	H	H	Et
	1-90	CH ₂ Cl	H	H	H	H
20	1-91	C ₆ H ₅ OCH ₂	CH ₂ NMe ₂	H	H	Et
	1-92	CH ₂ OMe	H	H	H	Et
	1-93	CH ₂ SMc	H	H	H	Me
25	1-94	CH ₂ SMc	H	H	H	H
	1-95	4-NO ₂ C ₆ H ₄	NO ₂	H	H	Et
	1-96	4-NO ₂ C ₆ H ₄	NO ₂	H	H	H
30	1-97	2,4-(NO ₂) ₂ C ₆ H ₃	NO ₂	H	H	H
	1-98	2-thiazolyl	H	H	H	H
	1-99	4-Me, 3-NO ₂ C ₆ H ₃	NO ₂	H	H	H
35	1-100	2-Me, 4-tBuC ₆ H ₃	H	H	H	Et
	1-101	2-Me, 4-tBuC ₆ H ₃	H	H	H	H
	1-102	2-Me, 5-tBuC ₆ H ₃	H	H	H	Et
40	1-103	2-Me, 5-tBuC ₆ H ₃	H	H	H	H
	1-104	2,4-Me ₂ C ₆ H ₃	H	H	H	H
	1-105	3,4-Me ₂ C ₆ H ₃	H	H	H	H
45	1-106	2,3,4,5-Me ₄ C ₆ H	H	H	H	Et
	1-107	2,3,4,5-Me ₄ C ₆ H	H	H	H	H

50

55

Table 4 (continued)

Compound No.	R ¹	R ²	R ³	R ⁴	R ⁵
1-108	2,5-El,C ₆ H ₃	H	H	H	El
1-109	2,5-El ₂ C ₆ H ₃	H	H	H	H
1-110	4-ElC ₆ H ₄	H	H	H	H
1-111	4-ElC ₆ H ₄	H	H	H	El
1-112	2,5-Cl ₂ C ₆ H ₃	H	H	H	H
1-113	2,5-(MeO) ₂ C ₆ H ₃	H	H	H	H
1-114	2-OMe,5-ClC ₆ H ₃	H	H	H	H
1-115	2-OMe,5-MeC ₆ H ₃	H	H	H	H
1-116	2-SMe,5-t-BuC ₆ H ₃	H	H	H	H
1-117	2-SMe,5-MeC ₆ H ₃	H	H	H	H
1-118	2-Me,4-MeSC ₆ H ₃	H	H	H	El
1-119	C ₆ H ₅	CHO	H	H	El
1-120	C ₆ H ₅	CHO	H	H	H
1-121	C ₆ H ₅	CN	H	H	El
1-122	C ₆ H ₅	CN	H	H	H
1-123	COOEt	H	H	H	El
1-124	COOEt	NO ₂	H	H	H
1-125	H	NO ₂	H	H	H
1-126	4-SO ₂ HC ₆ H ₄	H	H	H	H
1-127	Me	SO ₂ H	H	H	El
1-128	Me	SO ₂ H	H	H	H
1-129	Me	SO ₂ NHMe	H	H	El
1-130	Me	SO ₂ NHMe	H	H	H
1-131	Me	SO ₂ Cl	H	H	El
1-132	OH	COOEt	H	H	El
1-133	Cl	COOEt	H	H	El

Table 4 (continued)

Compound No.	R ¹	R ²	R ³	R ⁴	R ⁵
1-134	Cl	COOH	H	H	H
1-135	Cl	H	H	H	H
1-136	Me	NH ₂	H	H	Et
1-137	Me	C ₆ H ₅ CH=N	H	H	H
1-138	C ₆ H ₅ O	H	H	H	H
1-139	2-FC ₆ H ₄	H	H	H	Et
1-140	4-FC ₆ H ₄	H	H	H	Et
1-141	4-FC ₆ H ₄	H	H	H	H
1-142	2,4-F ₂ C ₆ H ₃	H	H	H	Et
1-143	2,4-F ₂ C ₆ H ₃	H	H	H	H
1-144	2,6-F ₂ C ₆ H ₃	H	H	H	Et
1-145	2,6-F ₂ C ₆ H ₃	H	H	H	H
1-146	Me	NO ₂	H	H	Et
1-147	2-thiazolyl	H	H	H	Et
1-148	2-SMe, 5-MeC ₆ H ₃	H	H	H	H
1-149	2-Me, 4-MeSC ₆ H ₃	H	H	H	Et
1-150	4-FC ₆ H ₄	H	H	H	H
1-151	2,4-(i-Pr) ₂ C ₆ H ₃	H	H	H	Et
1-152	2,4-(i-Pr) ₂ C ₆ H ₃	H	H	H	H
1-153	2-phenyl-imidazo[1,2-b]pyridazine-8-carboxylic acid				
1-154	6-chloro-2-phenyl-imidazo[1,2-b]pyridazine-8-carboxylic acid				

Table 5

Compound No.	m. p. (°C)	NMR (δ value)
1-1	67~68	4.13(3H, s), 6.90(1H, t, J=6.75Hz), 7.70(1H, d, J=0.9Hz), 7.80(1H, d, J=0.9Hz), 8.37(1H, dd, J=6.75Hz, 1.2Hz). (CDCl ₃)
1-2	210 (decomp.)	7.70(1H, d, J=7.5Hz), 8.20(1H, d, J=1.5Hz), 8.55(1H, d, J=7.5Hz), 8.65(1H, d, J=1.5Hz), 9.32(1H, d, J=7.5Hz). (DMSO-d ₆)
1-3	oil	2.45(3H, s), 4.03(3H, s), 6.82(1H, t, J=6.75Hz), 7.45(1H, s), 7.95(1H, d, J=6.75Hz), 8.25(1H, d, J=6.75Hz). (CDCl ₃)
1-4		2.50(3H, s), 7.45(1H, t, J=6.75Hz), 8.15(1H, s), 8.25(1H, d, J=6.75Hz), 9.00(1H, d, J=6.75Hz). (DMSO-d ₆)
1-5	132~134 (HBr salt)	1.32(3H, t, J=7.0Hz), 2.95(2H, q, J=7.0Hz), 4.05(3H, s), 7.60(1H, d, J=7.5Hz), 8.35(1H, s), 8.50(1H, d, J=6.75Hz), 9.25(1H, d, J=6.75Hz). (DMSO-d ₆)
1-6	125~127	1.38(3H, t, J=7.5Hz), 3.00(2H, q, J=7.5Hz), 7.62(1H, t, J=6.75Hz), 8.50(1H, d, J=6.75Hz), 8.55(1H, s), 9.45(1H, d, J=6.75Hz). (DMSO-d ₆)
1-8	oil	1.40(6H, d, J=7.5Hz), 3.00-3.50(1H, m), 4.00(3H, s), 6.75(1H, t, J=6.75Hz), 7.45(1H, s), 7.90(1H, d, J=6.75Hz), 8.26(1H, d, J=6.75Hz, 1.5Hz). (DMSO-d ₆)
1-9	135~137	1.30(6H, d, J=7.5Hz), 3.00-3.60(1H, m), 7.07(1H, t, J=6.75Hz), 7.85(1H, s), 7.99(1H, d, J=6.75Hz), 8.75(1H, d, J=6.75Hz). (DMSO-d ₆)

Table 5 (continued)

Compound No.	m. p. (°C)	NMR (δ value)
1-11	157~158 (HBr salt)	1.48(9H, s), 4.03(3H, s), 7.58(1H, t, J=6.75Hz), 8.33(1H, s), 8.45(1H, d, J=6.75Hz), 9.12(1H, t, J=6.75Hz). (DMSO-d ₆)
1-12	228	1.50(9H, s), 7.69(1H, t, J=6.3Hz), 8.40-8.60(2H, m), 9.26(1H, d, J=6.3Hz). (DMSO-d ₆)
1-13	oil	1.45(3H, t, J=6.0Hz), 4.55(2H, q, J=6.0Hz), 7.05(1H, t, J=6.75Hz), 7.70(1H, s), 8.00(1H, d, J=6.75Hz), 8.28(1H, d, J=6.75Hz). (CDCl ₃)
1-14		7.56(1H, t, J=6.75Hz), 8.20(1H, s), 8.38(1H, d, J=6.75Hz), 8.90(1H, d, J=6.75Hz). (DMSO-d ₆)
1-15	oil	2.50(3H, s), 4.05(3H, s), 6.95(1H, t, J=6.75Hz), 8.00(1H, d, J=6.75Hz), 9.00(1H, d, J=6.75Hz). (CDCl ₃)
1-17	123~124	2.20(6H, s), 2.50(3H, s), 3.65(2H, s), 6.73(1H, t, J=6.75Hz), 7.95(1H, d, J=6.75Hz), 8.42(1H, d, J=6.75Hz). (CDCl ₃)
1-22	255(sub-limed)	3.20(3H, s), 8.04(1H, t, J=6.75Hz), 9.09(1H, d, J=6.75Hz), 10.04(1H, d, J=6.75Hz). (CF ₃ COOD)
1-24	oil	4.05(3H, s), 6.83(1H, t, J=7.5Hz), 7.35-7.60(3H, m), 7.95(1H, s), 7.98-8.15(3H, m), 8.30(1H, d, J=7.5Hz). (CDCl ₃)
1-26	226	7.40-7.70(4H, m), 7.95-8.10(2H, m), 8.33(1H, d, J=6.75Hz), 8.80(1H, s), 9.10(1H, d, J=6.75Hz). (DMSO-d ₆)
1-27	oil	2.60(3H, s), 4.05(3H, s), 6.88(1H, t, J=6.75Hz), 7.25-7.40(3H, m), 7.80(1H, s), 7.90-8.10(1H, m), 8.35(1H, d, J=6.75Hz). (CDCl ₃)

Table 5 (continued)

Compound No.	m. p. (°C)	NMR (δ value)
1-28	220(sub-limed)	2.38(3H, s), 7.30-7.80(5H, m), 8.50(1H, J=6.75Hz), 8.75(1H, s), 9.28(1H, d, J=6.75Hz). (DMSO-d ₆)
1-30		2.48(3H, s), 4.03(3H, s), 7.30-7.90(5H, m), 8.42(1H, d, J=6.75Hz), 8.87(1H, s), 9.15(1H, d, J=6.75Hz). (DMSO-d ₆)
1-31	225~227	2.40(3H, s), 7.10-7.50(3H, m), 7.70-7.90(2H, m), 8.10(1H, d, J=6.75Hz), 8.65(1H, s), 8.90(1H, d, J=6.75Hz). (DMSO-d ₆)
1-32	122~124	2.35(3H, s), 4.06(3H, s), 6.80(1H, d, J=6.75Hz), 7.25(2H, d, J=8.25Hz), 7.85-8.05(3H, m), 7.90(1H, s), 8.28(1H, dd, J=6.75Hz, 1.5Hz). (DMSO-d ₆)
1-33	178~180	2.38(3H, s), 7.30-7.50(3H, m), 7.85(2H, d, J=8.25Hz), 8.25(1H, d, J=6.75Hz), 8.70(1H, s), 9.04(1H, d, J=6.75Hz). (DMSO-d ₆)
1-34	233~235	2.33(3H, s), 2.48(3H, s), 7.02-7.30(2H, m), 7.67(1H, m), 8.02(1H, dd, J=7.5Hz, 1.5Hz), 8.37(1H, s), 8.85(1H, dd, J=7.5Hz, 1.5Hz). (DMSO-d ₆)
1-36	(HBr salt)	4.00(3H, s), 4.08(3H, s), 7.10-7.40(2H, m), 7.50-7.80(2H, m), 7.93(1H, dd, J=1.5Hz, 7.5Hz), 8.54(1H, d, J=6.75Hz), 8.95(1H, s), 9.34(1H, d, J=6.75Hz). (DMSO-d ₆)
1-37	238~240	4.00(3H, s), 7.00-7.60(4H, m), 8.05(1H, dd, J=1.5Hz, 7.5Hz), 8.27(1H, d, J=6.75Hz), 8.75(1H, s), 9.10(1H, d, J=6.75Hz). (DMSO-d ₆)

Table 5 (continued)

Compound No.	m. p. (°C)	NMR (δ value)
1-38	172~174 (HBr salt)	4.00(3H, s), 4.17(3H, s), 7.20(1H, m), 7.50-7.80(4H, m), 8.54(1H, d, J=6.75Hz), 8.99(1H, s), 9.25(1H, d, J=6.75Hz). (DMSO _d ₆)
1-39	209~211	3.90(3H, s), 7.10(1H, m), 7.30-7.75(4H, m), 8.48(1H, d, J=6.75Hz), 9.00(1H, s), 9.25(1H, d, J=6.75Hz). (DMSO _d ₆)
1-40	oil	3.84(3H, s), 4.05(3H, s), 6.83(1H, d, J=6.75Hz), 7.00(3H, d, J=8.25Hz), 7.80-8.10(4H, m), 8.25(1H, dd, J=6.75Hz, 1.5Hz). (CDCl ₃)
1-41	171~173	3.78(3H, s), 7.05(1H, d, J=8.25Hz), 7.30(3H, t, J=6.75Hz), 7.88(2H, d, J=6.75Hz), 8.60(1H, s), 8.98(1H, d, J=6.75Hz). (DMSO _d ₆)
1-42	224~225 (HBr salt)	1.43(3H, t, J=6.6Hz), 3.88(3H, s), 3.90(3H, s), 4.47(2H, q, J=6.6Hz), 7.15(1H, d, J=9.0Hz), 7.48-7.68(2H, m), 8.42(1H, dd, J=7.5Hz, 1.5Hz), 8.88(1H, s), 9.12(1H, d, J=7.5Hz). (DMSO _d ₆)
1-43	243~245	3.85(3H, s), 3.90(3H, s), 7.10(1H, d, J=9.0Hz), 7.40-7.78(2H, m), 8.35(1H, d, J=7.5Hz), 8.83(1H, s), 9.10(1H, d, J=7.5Hz). (DMSO _d ₆)
1-45	205(sub-limed)	7.25(1H, t, J=6.3Hz), 7.40-7.60(3H, m), 8.00-8.30(2H, m), 8.84(1H, s), 9.00(1H, d, J=6.75Hz). (DMSO _d ₆)
1-46	220(sub-limed) (HBr salt)	4.05(3H, s), 7.50-7.80(3H, m), 7.95(1H, s), 8.10(1H, br), 8.45(1H, d, J=6.75Hz), 8.96(1H, s), 9.15(1H, d, J=6.75Hz). (DMSO _d ₆)

Table 5 (continued)

Compound No.	m. p. (°C)	NMR (δ value)
1-47	225(sub-limed)	7.40-7.60(3H, m), 7.95(1H, m), 8.15(1H, br), 8.35(1H, d, J=6.75Hz), 8.92(1H, s), 9.11(1H, d, J=6.75Hz), (DMSO _d ₆)
1-48	132~133	4.05(3H, s), 6.85(1H, t, J=6.7Hz), 7.45(2H, d, J=8.3Hz), 7.90(1H, s), 7.80-8.10(3H, m), 8.30(1H, dd, J=6.75Hz, 1.5Hz), (CDCl ₃)
1-49	220~222	7.50-7.70(3H, m), 8.05(2H, d, J=8.3Hz), 8.50(1H, d, J=6.75Hz), 8.85(1H, s), 9.15(1H, d, J=6.75Hz), (DMSO _d ₆)
1-50	160~162 (HBr salt)	4.20(3H, s), 7.60-8.00(5H, m), 8.60-8.80(2H, m), 9.10(1H, d, J=7.78Hz), (DMSO _d ₆)
1-51	205(sub-limed)	7.41(1H, t, J=6.75Hz), 7.68(2H, d, J=8.25Hz), 7.94(2H, d, J=8.25Hz), 8.23(1H, d, J=6.75Hz), 8.85(1H, s), 9.08(1H, d, J=6.75Hz), (DMSO _d ₆)
1-52	157~158	4.00(3H, s), 7.08(1H, t, J=6.75Hz), 7.96(1H, d, J=6.75Hz), 8.35(4H, s), 8.78(1H, s), 8.85(1H, d, J=6.75Hz), (DMSO _d ₆)
1-53	240(sub-limed)	7.28(1H, t, J=6.75Hz), 8.20(1H, d, J=6.75Hz), 8.30-8.50(4H, m), 8.82(1H, s), 8.95(1H, d, J=6.75Hz), (DMSO _d ₆)
1-54	266	7.20(1H, t, J=6.75Hz), 7.25-7.55(3H, m), 8.10(1H, d, J=6.75Hz), 8.18-8.40(1H, m), 8.54(1H, d, J=4.5Hz), 8.95(1H, d, J=6.75Hz), (DMSO _d ₆)
1-56	199~201	2.48(6H, m), 7.15-7.70(4H, m), 8.32(1H, d, J=6.75Hz), 8.55(1H, s), 9.04(1H, d, J=6.75Hz), (DMSO _d ₆)
1-60	97~98	4.18(3H, s), 6.99(1H, t, J=6.9Hz), 7.25-7.63(3H, m), 7.93-8.38(4H, m), (CDCl ₃)
1-61	194~196	7.26(1H, t, J=7.25Hz), 7.92-8.25(3H, m), 8.64(1H, dd, J=1.5Hz, 7.2Hz), (DMSO _d ₆)

Table 5 (continued)

Compound No.	m. p. (°C)	NMR (δ value)
1-63	129~131	4.08(3H, s), 6.80(3H, t, J=6.3Hz), 7.21-7.35(3H, m), 7.35-7.62(4H, m), 7.65-7.82(3H, m), 7.98(1H, d, J=6.3Hz), 8.08(1H, d, J=6.3Hz). (CDCl ₃)
1-71	oil	1.43(3H, t, J=6.0Hz), 4.48(2H, q, J=6.0Hz), 7.00(1H, t, J=6.3Hz), 8.01(1H, dd, J=7.5Hz, 0.8Hz), 8.42(1H, dd, J=7.5Hz, 0.8Hz), 8.00-8.10(1H, m). (CDCl ₃)
1-72	203~205	7.20(1H, t, J=6.0Hz), 8.55(1H, dd, J=9.0Hz, 1.5Hz), 8.60-8.67(1H, m), 8.83(1H, dd, J=9.0Hz, 1.5Hz). (DMSO-d ₆)
1-79	89~91	6.71-6.70(2H, m), 6.70-6.95(2H, m), 7.21-7.35(3H, m), 7.35-7.62(4H, m), 7.65-7.82(3H, m), 8.08(1H, d, J=6.3Hz). (DMSO-d ₆)
1-81	250(sub-limed) (NBr salt)	2.50(3H, s), 4.05(3H, s), 7.48-7.70(3H, m), 7.88-8.08(2H, m), 8.40(1H, d, J=1.0Hz), 8.80(1H, s), 9.02(1H, d, J=1.0Hz). (DMSO-d ₆)
1-82	250~252	2.40(3H, s), 7.39-7.65(3H, m), 7.95-8.10(2H, m), 8.09(1H, d, J=1.5Hz), 8.50(1H, s), 8.78(1H, d, J=1.5Hz). (DMSO-d ₆)
1-83	157~158	1.50(3H, t, J=6.3Hz), 2.41(3H, s), 2.55(3H, s), 4.58(2H, q, J=6.3Hz), 6.42(1H, s), 7.20-7.50(4H, m), 7.65(1H, s), 7.85-8.10(2H, m). (CDCl ₃)

Table 5 (continued)

Compound No.	m.p. (°C)	NMR (δ value)
1-84	121~122	2.68(3H,s), 2.71(3H,s), 7.05(1H,s), 7.40-7.70(4H,m), 8.60(1H,s). (DMSO-d ₆)
1-85		2.18(3H,s), 3.94(2H,s), 4.02(3H,s), 6.81(1H,t, J=6.6Hz), 7.68(1H,s), 7.93(1H,dd, J=6.6Hz, 1.5Hz), 8.28(1H, dd, J=6.6Hz, 1.5Hz). (DMSO-d ₆)
1-86	250(sub- limed)	5.38(2H,s), 6.88-7.20(3H,m), 7.21-7.5 5(3H,m), 8.27(1H,d, J=7.5Hz), 8.42(1H, s), 9.05(1H,d, J=7.5Hz). (DMSO-d ₆)
1-88	255(sub- limed)	4.48(2H,s), 7.15-7.55(6H,m), 8.13(1H, s), 8.10(1H,d, J=6.6Hz), 8.89(1H,d, J= 6.6Hz). (DMSO-d ₆)
1-89	138~139	1.42(3H,t, J=6.3Hz), 4.47(2H,q, J= 6.3Hz), 4.86(2H,s), 6.87(1H,t, J=7.5Hz) , 7.72(1H,s), 7.93(1H,dd, J=7.5Hz, 1.5Hz), 8.28(1H,dd, J=7.5Hz, 1.5Hz). (CDCl ₃)
1-90	250 (decomp.)	4.86(2H,s), 6.87(1H,t, J=7.5Hz), 7.72(1H,s), 7.93(1H,dd, J=7.5Hz, 1.5Hz) , 8.28(1H,dd, J=7.5Hz, 1.5Hz). (CDCl ₃)
1-94	oil	2.18(3H,s), 3.94(2H,s), 4.02(3H,s), 6.81(1H,t, J=6.6Hz), 7.68(1H,s), 7.93(1H,dd, J=6.6Hz, 1.5Hz), 8.28(1H, dd, J=6.6Hz, 1.5Hz). (CDCl ₃)

Table 5 (continued)

Compound No.	m.p.(°C)	NMR (δ value)
I-96	more than 300	7.60(1H,t,J=7.8Hz), 8.04-8.52(5H,m), 9.56-9.72(1H,m). (DMSO-d ₆)
I-98	210(sub-limed)	7.22(1H,t,J=6.75Hz), 7.83(1H,d,J=3.0Hz), 8.00(1H,d,J=3.0Hz), 8.05(1H,d,J=6.75Hz), 8.67(1H,s), 8.92(1H,d,J=6.75Hz). (DMSO-d ₆)
I-100	oil	1.32(9H,s), 1.45(3H,t,J=7.0Hz), 2.60(3H,s), 4.52(2H,q,J=7.0Hz), 6.75(1H,t,J=6.75Hz), 7.20-7.40(2H,m), 7.70-8.00(3H,m), 8.33(1H,d,J=6.75Hz). (CDCl ₃)
I-101	191~192	1.30(9H,s), 2.56(3H,s), 7.20(1H,t,J=6.75Hz), 7.36(2H,m), 7.82(1H,d,J=9.0Hz), 8.40(1H,s), 8.94(1H,d,J=6.75Hz). (DMSO-d ₆)
I-102	oil	1.35(9H,s), 1.50(3H,t,J=7.0Hz), 2.51(3H,s), 4.51(2H,q,J=7.0Hz), 6.78(1H,t,J=6.75Hz), 7.05-7.40(2H,m), 7.76(1H,s), 7.90(1H,d,J=6.75Hz), 8.05(1H,m), 8.32(1H,d,J=6.75Hz). (CDCl ₃)
I-103	194~195	1.32(9H,s), 2.45(3H,s), 7.15(1H,t,J=6.75Hz), 7.30(2H,m), 7.85(1H,m), 8.08(1H,d,J=6.75Hz), 8.45(1H,s), 8.90(1H,d,J=6.75Hz). (DMSO-d ₆)
I-104	240~241	2.37(3H,s), 2.45(3H,s), 7.17(1H,d,J=7.5Hz), 7.23(1H,s), 7.60(1H,d,J=6.6Hz), 7.45(1H,t,J=6.6Hz), 8.28(1H,dd,J=6.6,1.5Hz), 8.52(1H,s), 9.05(1H,dd,J=6.6,1.5Hz). (DMSO-d ₆)

Table 5 (continued)

Compound No.	m.p.(°C)	NMR (δ value)
I 105	249~250	2.30(3H,s), 2.34(3H,s), 7.31(1H,d, J=6.6Hz), 7.42(1H,d, J=7.5Hz), 7.72(1H,dd, J=7.5Hz, 1.5Hz), 7.77(1H,d, J=1.5Hz), 8.28(1H,dd, J=6.6, 1.5Hz), 8.70(1H,s), 9.03(1H,dd, J=6.6, 1.5Hz). (DMSO-d ₆)
I 106	211~212 (HBr salt)	1.45(3H,t, J=7.0Hz), 2.20-2.45(2H,br), 4.55(2H,q, J=7.0Hz), 7.19(1H,s), 7.63(1H,d, J=6.75Hz), 8.52(1H,d, J=6.75Hz), 8.52(1H,d, J=6.75Hz), 8.59(1H,s), 9.33(1H,d, J=6.75Hz). (DMSO-d ₆)
I 107	265~266	2.20-2.45(2H,m), 7.15(1H,s), 7.67(1H,d, J=6.75Hz), 8.45-8.60(2H,m), 9.29(1H,d, J=6.75Hz). (DMSO-d ₆)
I 110	212~213 (HBr salt)	1.28(3H,t, J=7.0Hz), 1.48(3H,t, J=7.0Hz), 2.74(2H,q, J=7.0Hz), 4.57(2H,q, J=7.0Hz), 7.43(2H,d, J=7.5Hz), 7.64(1H,t, J=6.75Hz), 7.95(2H,d, J=7.5Hz), 8.53(1H,d, J=6.75Hz), 8.88(1H,s), 9.25(1H,d, J=6.75Hz). (DMSO-d ₆)
I 111	214~215	1.25(3H,t, J=7.0Hz), 2.75(2H,q, J=7.0Hz), 7.25-7.60(3H,m), 7.91(2H,d, J=7.5Hz), 8.33(1H,d, J=6.75Hz), 8.79(1H,s), 9.10(1H,d, J=6.75Hz). (DMSO-d ₆)

Table 5 (continued)

Compound No.	m. p. (°C)	NMR (δ value)
1-112	260(sub-limed)	2.35(3H, s), 3.98(3H, s), 7.15(1H, t, J=7.5Hz), 7.30(1H, dd, J=8.0, 1.5Hz), 7.45(1H, d, J=7.5Hz), 7.87(1H, d, J=1.5Hz), 8.25(1H, d, J=7.5Hz), 8.73(1H, s), 9.05(1H, d, J=7.5Hz). (DMSO-d ₆)
1-113	225(sub-limed)	2.37(3H, s), 2.45(3H, s), 7.17(1H, d, J=7.5Hz), 7.23(1H, s), 7.60(1H, d, J=6.6Hz), 7.45(1H, t, J=6.6Hz), 8.28(1H, dd, J=6.6, 1.5Hz), 8.52(1H, s), 9.05(1H, dd, J=6.6, 1.5Hz). (DMSO-d ₆)
1-114	283~285	4.00(3H, s), 7.33(1H, t, J=6.6Hz), 7.49(1H, d, J=6.3Hz), 7.69(1H, dd, J=6.3, 2.5Hz), 8.12(1H, d, J=2.5Hz), 8.40(1H, d, J=6.3Hz), 8.89(1H, s), 9.16(1H, d, J=6.3Hz). (DMSO-d ₆)
1-115	235~237	2.35(3H, s), 3.98(3H, s), 7.15(1H, t, J=7.5Hz), 7.30(1H, dd, J=8.0, 1.5Hz), 7.45(1H, d, J=7.5Hz), 7.87(1H, d, J=1.5Hz), 8.25(1H, d, J=7.5Hz), 8.73(1H, s), 9.05(1H, d, J=7.5Hz). (DMSO-d ₆)
1-118	164~167 (HBr salt)	1.45(3H, t, J=7.0Hz), 2.44(3H, s), 2.53(3H, s), 4.55(2H, q, J=7.0Hz), 7.15-7.40(2H, m), 7.50-7.75(2H, m), 8.47(1H, d, J=6.75Hz), 8.64(1H, s), 9.22(1H, d, J=6.75Hz). (DMSO-d ₆)

Table 5 (continued)

Compound No.	m.p.(°C)	NMR (δ value)
1-119	139	1.48(3H, t, J=6.9Hz), 4.53(2H, q, J=6.9Hz), 7.20(1H, t, J=7.2Hz), 7.50-7.65(3H, m), 7.82-8.03(2H, m), 8.27(1H, dd, J=1.35, 7.2 Hz), 9.90(1H, dd, J=1.35, 7.2Hz), 10.15 (1H, s). (CDCl ₃)
1-120	214~216	7.35-7.70(4H, m), 7.88-8.09(2H, m), 8.32(1 H, dd, J=1.35, 6.6Hz), 9.80(1H, dd, J=1.35, 6.6Hz), 10.12(1H, s). (DMSO-d ₆)
1-121	87~89	1.49(3H, t, J=7.5Hz), 4.52(2H, q, J=7.5Hz), 6.99(1H, t, J=7.35Hz), 7.36-7.69(3H, m), 8.01(1H, dd, J=1.35, 7.35Hz), 8.17-8.49(3 H, m). (CDCl ₃)
1-122	200~201	7.28(1H, t, J=6.9Hz), 7.40-7.70(3H, m), 8.00-8.23(3H, m), 8.68(1H, dd, J=1.35, 6.9 Hz). (DMSO-d ₆)
1-123	97	1.43(3H, t, J=3.9Hz), 1.45(3H, t, J=3.9Hz), 4.03-4.68(4H, m), 6.99(1H, t, J=6.9Hz), 7. 94-8.12(1H, m), 8.30(1H, s), 8.40(1H, d, J= 6.9Hz). (CDCl ₃)
1-124	139~140	1.39(6H, t, J=7.8Hz), 4.45(2H, q, J=7.8Hz), 4.48(2H, q, J=7.8Hz), 7.63(1H, t, J=7.65Hz), 8.37(1H, dd, J=1.35, 7.65Hz), 9.52(1H, dd, J=1.35, 7.65Hz). (DMSO-d ₆)
1-125	> 300	7.67(1H, t, J=7.5Hz), 8.30(1H, dd, J=1.35, 7.5Hz), 8.80(1H, s), 9.55(1H, dd, J=1.35, 7.5Hz). (DMSO-d ₆)

Table 5 (continued)

Compound No.	m. p. (°C)	NMR (δ value)
1-127	247~250 (decomp.)	1.40(3H, t, J=7.5Hz), 2.71(3H, s), 2.90- 4.24(1H, br), 4.51(2H, q, J=7.5 Hz), 7.72 (1H, t, J=7.8Hz), 8.57(1H, dd, J=1.35, 7.8 Hz), 9.30(1H, dd, J=1.35, 7.8Hz). (DMSO-d ₆)
1-128	> 300	2.71(3H, s), 7.70(1H, t, J=7.5Hz), 8.52 (1H, dd, J=1.35, 7.5Hz), 9.30(1H, dd, J= 1.35, 7.5Hz). (DMSO-d ₆)
1-129	184~185	1.42(3H, t, J=7.5Hz), 2.65(3H, s), 2.77(3H, s), 4.47(2H, q, J=7.5Hz), 5.25(1H, br), 7.03 (1H, t, J=7.5Hz), 8.11(1H, dd, J=1.35, 7.5Hz) , 8.87(1H, dd, J=1.35, 7.5Hz). (CDCl ₃)
1-130	235~236	2.49(3H, d, J=5.4Hz), 2.70(3H, s), 5.40- 6.91(1H, br), 7.60(1H, t, J=6.6Hz), 8.34- 8.74(2H, m), 9.02-9.20(1H, m). (DMSO-d ₆)
1-131	182~183	1.47(3H, t, J=7.5Hz), 2.85(3H, s), 4.53(2H, q, J=7.5Hz), 7.30(1H, t, J=7.1Hz), 8.28(1H, dd, J=1.5, 7.1Hz), 8.98(1H, dd, J=1.5, 7.1 Hz). (CDCl ₃)

Table 5 (continued)

Compound No.	m. p. (°C)	NMR (δ value)
1-132	(HBr salt)	1.20-1.49(6H, m), 4.12-4.60(4H, m), 7.20-7.42(1H, m), 8.11(1H, dd, J=1.35, 7.8Hz), 9.67(1H, dd, J=1.35, 7.2Hz). (DMSO-d ₆)
1-133	105~106	1.44(6H, t, J=7.5Hz), 4.31-4.66(4H, m), 7.15(1H, t, J=7.5Hz), 8.17(1H, dd, J=1.35, 7.5Hz), 9.57(1H, dd, J=1.35, 7.5Hz). (CDCl ₃)
1-134	210~212 (decomp.)	5.40-8.00(2H, br), 7.38(1H, t, J=6.6Hz), 8.18(1H, dd, J=1.35, 6.6Hz), 9.55(1H, dd, J=1.35, 6.6Hz). (DMSO-d ₆)
1-135	237	7.25(1H, t, J=7.5Hz), 8.19(1H, dd, J=1.35, 7.5Hz), 7.65-8.29(1H, br), 8.35(1H, s), 8.88(1H, dd, J=1.35, 7.5Hz). (DMSO-d ₆)
1-136	amorphous	1.42(3H, t, J=7.2Hz), 2.43(3H, s), 2.91(2H, br), 4.47(2H, q, J=7.2Hz), 6.81(1H, t, J=7.5Hz), 7.82(1H, dd, J=1.35, 7.5Hz), 8.20(1H, dd, J=1.35, 7.5Hz). (CDCl ₃)
1-137	231~233	2.70(3H, s), 7.20(3H, t, J=6.9Hz), 7.47-7.68(3H, m), 7.93-8.21(3H, m), 8.76-8.95(2H, m). (DMSO-d ₆)
1-139	270(decomp.) (HBr salt)	1.42(3H, t, J=7.0Hz), 4.54(2H, q, J=7.0Hz), 7.30-7.70(4H, m), 8.00-8.25(1H, m), 8.39(1H, d, J=6.75Hz), 8.77(1H, d, J=4.5Hz), 9.20(1H, d, J=6.75Hz). (DMSO-d ₆)

Table 5 (continued)

Compound No.	m.p.(°C)	NMR (δ value)
1-140	177~178 (HBr salt)	1.42(3H,t,J=7.0Hz), 4.55(2H,q,J=7.0Hz), 7.40(2H,t,J=9.0Hz), 7.62(1H,t,J=6.75Hz), 8.03(2H,dd,J=9.0, 6.0Hz), 8.48(1H,d,J=6.75Hz), 8.88(1H,s), 9.20(1H,d,J=6.75Hz). (DMSO-d ₆)
1-141	220 (sublimed)	7.20 7.50(3H,m), 8.05(2H,dd,J=9.0, 6.0Hz), 8.28(1H,d,J=6.75Hz), 8.73(1H,s), 9.06(1H,d,J=6.75Hz). (DMSO-d ₆)
1-142	97~99	1.50(3H,t,J=7.0Hz), 4.65(2H,q,J=7.0Hz), 6.80 7.20(3H,m), 7.90(1H,d,J=6.75Hz), 8.06(1H,d,J=4.0Hz), 8.34(1H,d,J=6.75Hz), 8.45 8.65(1H,m)(CDCl ₃)
1-143	240 (sublimed)	7.00-7.40(2H,m), 7.65-8.10(2H,m), 8.56 (1H,s), 8.85(1H,d,J=6.75Hz), 9.01(1H,d, J=6.75Hz). (CF ₃ COOD)
1-144	206~208 (HBr salt)	1.41(3H,t,J=7.0Hz), 4.55(2H,q,J=7.0Hz), 7.20 7.90(4H,m), 8.55(1H,d,J=6.75Hz), 8.88(1H,s), 8.32(1H,d,J=6.75Hz). (DMSO-d ₆)
1-145	280~282	7.15-7.80(3H,m), 8.12(1H,d,J=6.75Hz), 8.55(1H,d,J=1.5Hz), 8.99(1H,d,J=6.75Hz). (DMSO-d ₆)

Table 5 (continued)

Compound No.	m.p.(°C)	NMR (δ value)
1-146	143~144	1.45(3H,t,J=7.0Hz), 2.78(3H,s), 4.42(2H,q,J=7.0Hz), 7.50(1H,d,J=6.75Hz), 8.25(1H,d,J=6.75Hz), 9.55(1H,d,J=6.75Hz). (DMSO-d ₆)
1-147	143~146 (HBr salt)	1.38(3H,t,J=7.0Hz), 4.42(2H,q,J=7.0Hz), 7.30(1H,m), 8.88(2H,m), 8.30(1H,m), 8.70(2H,m). (DMSO-d ₆)
1-151	oil	1.30(12H,d,J=6.0Hz), 1.45(3H,t,J=7.0Hz), 2.95(1H,m,J=6.0Hz), 3.48(1H,m,J=6.0Hz), 4.45(2H,q,J=7.0Hz), 6.75-7.75(5H,m), 7.95(1H,d,J=6.75Hz), 8.35(1H,d,J=6.75Hz). (CDCl ₃)
1-152	99~101	1.15-1.40(12H,m), 2.80-3.40(2H,m), 7.10-7.60(4H,m), 8.35(1H,d,J=6.75Hz), 8.48(1H,s), 9.09(1H,d,J=6.75Hz). (DMSO-d ₆)




Table 6

	Compound No.	R ¹	R ²	R ³	R ⁴	R ⁵
5	2-1	H	H	H	H	A-1
	2-2	Me	H	H	H	A-1
	2-3	Me	H	H	H	A-2
10	2-4	Me	H	H	H	A-4
	2-5	Et	H	H	H	A-1
	2-6	nPr	H	H	H	A-1
15	2-7	iPr	H	H	H	A-1
	2-8	nBu	H	H	H	A-1
	2-9	tBu	H	H	H	A-1
20	2-10	H	Cl	H	H	A-1
	2-11	Me	Cl	H	H	A-1
	2-12	Me	Me	H	H	A-1
25	2-13	Me	CHO	H	H	A-1
	2-14	Me	NO ₂	H	H	A-1
	2-15	Me	CH ₂ NMe ₂	H	H	A-1
30	2-16	Me	CF ₂ CHF ₂	H	H	A-1
	2-17	Me	CH ₂ NMe ₂	H	H	A-2
	2-18	Me	CH ₂ NMe ₂	H	H	A-4
35	2-19	Me	CH ₂ NMe ₂ ·HCl*	H	H	A-4
	2-20	Me	CH ₂ $\overset{\text{O}}{\underset{\text{N}}{\text{C}}}$	H	H	A-1
	2-21	Me	CH ₂ S-iPr	H	H	A-4
40	2-22	Me	CH ₂ CH ₂ CN	H	H	A-4
	2-23	Me	CH=CHMe ₂	H	H	A-4
	2-24	C ₆ H ₅	H	H	H	A-1
45	2-25	C ₆ H ₅	H	H	H	A-2
	2-26	C ₆ H ₅	H	H	H	A-3

50

55

T a b l e 6

Compound No.	R ¹	R ²	R ³	R ⁴	R ⁵
2-27	C ₆ H ₅	H	H	H	A-4
2-28	C ₆ H ₅	H	H	H	A-5
2-29	C ₆ H ₅	H	H	H	A-6
2-30	C ₆ H ₅	H	H	H	A-7
2-31	C ₆ H ₅	H	H	H	A-8
2-32	C ₆ H ₅	H	H	H	A-9
2-33	C ₆ H ₅	H	H	H	A-10
2-34	C ₆ H ₅	H	H	H	A-11
2-35	C ₆ H ₅	H	H	H	A-12
2-36	C ₆ H ₅	H	H	H	A-13
2-37	C ₆ H ₅	H	H	H	A-14
2-38	C ₆ H ₅	H	H	H	A-15
2-39	C ₆ H ₅	H	H	H	A-16
2-40	C ₆ H ₅	H	H	H	A-17
2-41	C ₆ H ₅	H	H	H	A-18
2-42	C ₆ H ₅	H	H	H	A-19
2-43	C ₆ H ₅	H	H	H	A-20
2-44	C ₆ H ₅	H	H	H	A-21
2-45	C ₆ H ₅	H	H	H	A-22
2-46	C ₆ H ₅	H	H	H	A-23
2-47	C ₆ H ₅	H	H	H	A-24
2-48	C ₆ H ₅	H	H	H	A-25
2-49	C ₆ H ₅	H	H	H	A-26
2-50	C ₆ H ₅	H	H	H	A-27
2-51	C ₆ H ₅	H	H	H	A-28
2-52	C ₆ H ₅	H	H	H	A-29

Table 6

Compound No.	R ¹	R ²	R ³	R ⁴	R ^a
2-53	C ₆ H ₅	H	H	H	A-30
2-54	2-MeC ₆ H ₄	H	H	H	A-1
2-55	2-MeC ₆ H ₄	H	H	H	A-2
2-56	2-MeC ₆ H ₄	H	H	H	A-4
2-57	3-MeC ₆ H ₄	H	H	H	A-1
2-58	4-MeC ₆ H ₄	H	H	H	A-1
2-59	2,5-Me ₂ C ₆ H ₃	H	H	H	A-1
2-60	2,5-Me ₂ C ₆ H ₃	H	H	H	A-2
2-61	2,5-Me ₂ C ₆ H ₃	H	H	H	A-4
2-62	2,4,6-Me ₃ C ₆ H ₂	H	H	H	A-1
2-63	2-MeOC ₆ H ₄	H	H	H	A-1
2-64	3-MeOC ₆ H ₄	H	H	H	A-1
2-65	4-MeOC ₆ H ₄	H	H	H	A-1
2-66	3,4-(MeO) ₂ C ₆ H ₃	H	H	H	A-1
2-67	3,4-(MeO) ₂ C ₆ H ₃	H	H	H	A-4
2-68	2-ClC ₆ H ₄	H	H	H	A-1
2-69	3-ClC ₆ H ₄	H	H	H	A-1
2-70	4-ClC ₆ H ₄	H	H	H	A-1
2-71	4-BrC ₆ H ₄	H	H	H	A-1
2-72	4-NO ₂ C ₆ H ₄	H	H	H	A-1
2-73	2-FC ₆ H ₄	H	H	H	A-1
2-74	2-F, 4-MeC ₆ H ₃	H	H	H	A-1
2-75	2-Me, 4-MeSC ₆ H ₃	H	H	H	A-4
2-76	2,4,6-Cl ₃ C ₆ H ₂	H	H	H	A-1
2-77	C ₆ H ₅	CH ₂ NMe ₂	H	H	A-1
2-78	C ₆ H ₅	CH ₂ NMe ₂	H	H	A-2

Table 6

Compound No.	R ¹	R ²	R ³	R ⁴	R ⁿ
2-79	C ₆ H ₅	CH ₂ NMe ₂	H	H	A-4
2-80	C ₆ H ₅	CH ₂ NMe ₂ ·HO*	H	H	A-4
2-81	C ₆ H ₅	Cl	H	H	A-1
2-82	C ₆ H ₅	Me	H	H	A-4
2-83	C ₆ H ₅	C ₆ H ₅	H	H	A-4
2-84	C ₆ H ₅	CF ₂ CHF ₂	H	H	A-1
2-85	C ₆ H ₅	CHO	H	H	A-1
2-86	C ₆ H ₅	NO ₂	H	H	A-1
2-87	C ₆ H ₅	CN	H	H	A-1
2-88	C ₆ H ₅	CH ₂ CH ₂ CN	H	H	A-1
2-89	C ₆ H ₅	CH=CMe ₂	H	H	A-1
2-90	C ₆ H ₅	CH(OH)CCl ₃	H	H	A-1
2-91	C ₆ H ₅ CH ₂	H	H	H	A-1
2-92	CF ₃	H	H	H	A-1
2-93	Cl	H	H	H	A-1
2-94	Cl	Cl	H	H	A-1
2-95	CHO	H	H	H	A-2
2-96	CN	H	H	H	A-2
2-97	CH=CMe ₂	H	H	H	A-2
2-98	CH=NOEt	H	H	H	A-2
2-99	OMe	H	H	H	A-1
2-100	OMe	H	H	H	A-2
2-101	OMe	H	H	H	A-4
2-102	SMe	H	H	H	A-1
2-103	H	OMe	H	H	A-1
2-104	2-thienyl	H	H	H	A-1
2-105	2-furyl	H	H	H	A-1

Table 6

Compound No.	R ¹	R ²	R ³	R ⁴	R ⁵
2-106	2-pyridyl	H	H	H	A-1
2-107	C ₆ H ₅	H	5-Me	H	A-1
2-108	C ₆ H ₅	H	5-Me	H	A-2
2-109	C ₆ H ₅	H	5-Me	H	A-4
2-110	Me	H	5-Me	H	A-4
2-111	Me	CH ₂ NMe ₂	5-Me	H	A-2
2-112	C ₆ H ₅	H	5-Me	7-Me	A-1
2-113	C ₆ H ₅	H	5-CF ₃	7-CF ₃	A-1
2-114	C ₆ H ₅ OCH ₂	H	H	H	A-4
2-115	C ₆ H ₅ SCH ₂	H	H	H	A-4
2-116	C ₆ H ₅ SOCH ₂	H	H	H	A-4
2-117	C ₆ H ₅ SO ₂ CH ₂	H	H	H	A-4
2-118	C ₆ H ₅ OCH ₂	CH ₂ NMe ₂	H	H	A-4
2-119	MeOCH ₂	H	H	H	A-1
2-120	MeOCH ₂	CH ₂ N $\begin{array}{c} \diagup \diagdown \\ \text{O} \end{array}$	H	H	A-1
2-121	MeSCH ₂	H	H	H	A-1
2-122	Me $\overset{\text{O}}{\underset{ }{\text{S}}}$ CH ₂	H	H	H	A-1
2-123	MeSCH ₂	CH ₂ NMe ₂	H	H	A-1
2-124	MeSO ₂ CH ₂	H	H	H	A-4
2-125	$\begin{array}{c} \diagup \diagdown \\ \text{O} \end{array}$ NCH ₂	H	H	H	A-4
2-126	(EtO) ₂ P(O)CH ₂	H	H	H	A-4
2-127	Me ₂ NCSSCH ₂	H	H	H	A-1
2-128	ClCH ₂	H	H	H	A-1
2-129	CF ₃	C ₆ H ₅ NHCO	H	H	A-4
2-130	H	C ₆ H ₅ CO	H	H	A-2
2-131	H	C ₆ H ₅ C(OH)	H	H	A-2

Table 6

	Compound No.	R ¹	R ²	R ³	R ⁴	R ⁵
5	2-132	H	C ₆ H ₅ CH ₂	H	H	A-2
	2-133	H	Et	H	H	A-2
	2-134	C ₆ H ₅	H	H	H	A-4
10	2-135	2-MeC ₆ H ₄	CHO	H	H	A-1
	2-136	2-FC ₆ H ₄	H	H	H	A-4
	2-137	2-FC ₆ H ₄	H	H	H	A-2
	2-138	3,4-MeO ₂ C ₆ H ₃	H	H	H	"
15	2-139	2,5-Me ₂ C ₆ H ₃	H	6-Me	H	A-1
	2-140	4-FC ₆ H ₄	H	H	H	A-2
	2-141	2,4-F ₂ C ₆ H ₃	H	H	H	"
20	2-142	2,6-F ₂ C ₆ H ₃	H	H	H	"
	2-143	C ₆ H ₅	CH ₂ SO ₃ H	H	H	"
	2-144	4-Me ₂ NC ₆ H ₄	H	H	H	"
25	2-145	4-NO ₂ C ₆ H ₄	NO ₂	H	H	"
	2-146	C ₆ H ₅	CHO	H	H	"
	2-147	C ₆ H ₅	F	H	H	"
30	2-148	C ₆ H ₅	CH=NC ₆ H ₅	H	H	"
	2-149	4-Me, 3-NO ₂ C ₆ H ₃	NO ₂	H	H	"
	2-150	Me	H	H	H	A-11
35	2-151	Et	H	H	H	"
	2-152	2-MeC ₆ H ₄	H	H	H	"
	2-153	4-FC ₆ H ₄	H	H	H	"
40	2-154	Me	NO ₂	H	H	A-2
	2-155	4-C ₆ H ₅ -C ₆ H ₅	H	H	H	"
	2-156	C ₆ H ₅	H	H	H	"
45	2-157	C ₆ H ₅	CN	H	H	"

50

55

Table 6

	Compound No.	R ¹	R ²	R ³	R ⁴	R ^a
5	2-158	H	NO ₂	H	H	"
	2-159	4-Me, 3-NO ₂ C ₆ H ₃	H	H	H	"
	2-160	2, 4-(NO ₂) ₂ C ₆ H ₃	NO ₂	H	H	"
10	2-161	4-SO ₃ HC ₆ H ₄	H	H	H	"
	2-162	2, 5-Cl ₂ C ₆ H ₃	H	H	H	"
	2-163	2, 5-(MeO) ₂ C ₆ H ₃	H	H	H	"
15	2-164	Me	SO ₃ H	H	H	"
	2-165	Me	SO ₂ NHMe	H	H	"
	2-166	C ₆ H ₅	H	H	H	"
20	2-167	Cl	H	H	H	"
	2-168	4-NO ₂ C ₆ H ₄	H	H	H	"
	2-169	Me	NO ₂	H	H	HNCH(OEt)CONH ₂
25	2-170	Me	NO ₂	H	H	A-11
	2-171	2-thiazolyl	H	H	H	A-2
	2-272	CF ₃	H	H	H	HNCH(3-FC ₆ H ₄)CONH ₂
30	2-173	3-HOC ₆ H ₄	H	H	H	A-2
	2-174	2-HOC ₆ H ₄	H	H	H	"
	2-175	2-MeOC ₆ H ₄	H	H	H	"
35	2-176	3-MeOC ₆ H ₄	H	H	H	"
	2-177	4-MeOC ₆ H ₄	H	H	H	"
	2-178	2-ClC ₆ H ₄	H	H	H	"
40	2-179	3-ClC ₆ H ₄	H	H	H	"
	2-180	4-ClC ₆ H ₄	H	H	H	"
	2-181	2, 4-Me ₂ C ₆ H ₃	H	H	H	"
45	2-182	3, 4-Me ₂ C ₆ H ₃	H	H	H	"
	2-183	2-Me, 4-MeSC ₆ H ₃	H	H	H	"

50

55

Table 6

Compound No.	R ¹	R ²	R ³	R ⁴	R ⁵
2-184	2-Me, 4-tBuC ₆ H ₃	H	H	H	"
2-185	2-Me, 5-tBuC ₆ H ₃	H	H	H	"
2-186	2-Cl, 5-MeC ₆ H ₃	H	H	H	"
2-187	3-MeC ₆ H ₄	H	H	H	"
2-188	4-MeC ₆ H ₄	H	H	H	"
2-189	Me	N=CHC ₆ H ₅	H	H	"
2-190	OC ₆ H ₅	H	H	H	"
2-191	SC ₆ H ₅	H	H	H	"
2-192	OMe	H	H	H	"
2-193	C ₆ H ₅	H	5-OH	6-Cl	"
2-194	β -naphthyl	H	H	H	"
2-195	Me	NH ₂	H	H	"
2-196	2,3,4,5-Me ₄ C ₆ H	H	H	H	"
2-197	Et	H	H	H	"
2-198	2-EtC ₆ H ₄	H	H	H	"
2-199	3-EtC ₆ H ₄	H	H	H	"
2-200	4-EtC ₆ H ₄	H	H	H	"
2-201	4-BrC ₆ H ₄	H	H	H	"
2-202	2,5-Et ₂ C ₆ H ₃	H	H	H	"
2-203	2-Me, 5-ClC ₆ H ₃	H	H	H	"
2-204	2-Me, 5-EtC ₆ H ₃	H	H	H	"
2-205	2-Et, 5-MeC ₆ H ₃	H	H	H	"
2-206	2,4-(MeO) ₂ C ₆ H ₃	H	H	H	"
2-207	2-Me ₂ NCOC ₆ H ₄	H	H	H	"
2-208	2-MeOCH ₂ C ₆ H ₄	H	H	H	"
2-209	2-Me, 4-MeSOC ₆ H ₃	H	H	H	"

Compound No.	R ¹	R ²	R ³	R ⁴	R ⁶
2-210	2-Me, 4-MeSO ₂ C ₆ H ₃	H	H	H	"
5 2-211	5-Me, 2-MeOC ₆ H ₃	H	H	H	"
2-212	5-Cl, 2-MeOC ₆ H ₃	H	H	H	"
2-213	2, 4-(i-Pr) ₂ C ₆ H ₃	H	H	H	"
10 2-214	2, 5-(i-Pr) ₂ C ₆ H ₃	H	H	H	"
2-215	4-iPrC ₆ H ₄	H	H	H	"
2-216	5-Me, 2-MeSC ₆ H ₃	H	H	H	"
15 2-217	C ₆ H ₁₁	H	H	H	"
2-218	5-t-Bu, 2-MeSC ₆ H ₃	H	H	H	"
2-219	5-Cl, 2-MeSC ₆ H ₃	H	H	H	"
20 2-220	4-CNC ₆ H ₄	H	H	H	"
2-221	2-CF ₃ C ₆ H ₄	H	H	H	"
2-222	3-CF ₃ C ₆ H ₄	H	H	H	"
25 2-223	2-Me, 5-CF ₃ C ₆ H ₃	H	H	H	"
2-224	α-(imidazo[1, 2-a]pyridin-5-ylcarbonylamino)-(2-furyl)acetonitrile				
30 2-225	α-(imidazo[1, 2-a]pyridin-6-ylcarbonylamino)-(2-furyl)acetonitrile				
2-226	α-(3-chloro-2-phenyl-imidazo[1, 2-b]thiazol-5-ylcarbonylamino)-(2-furyl)acetonitrile				
35 2-227	α-(imidazo[1, 2-b]pyridazin-3-ylcarbonylamino)-(2-furyl)acetonitrile				
40 2-228	α-(6-methoxy-imidazo[1, 2-b]pyridazin-3-ylcarbonylamino)-(2-furyl)acetonitrile				
45 2-229	α-(pyrazolo[1, 2-b]pyrimidin-3-ylcarbonylamino)-(2-furyl)acetonitrile				

50

55

Compound No.	R ¹	R ²	R ³	R ⁴	R ⁵
2-230	α -(2-methylindolizin-8-ylcarbonylamino)-(2-thienyl)acetonitrile				
2-231	α -(2-phenyl-imidazo[1,2-b]pyridazin-8-ylcarbonylamino)-(2-thienyl)acetonitrile				
2-232	α -(6-chloro-2-phenyl-imidazo[1,2-b]pyridazin-8-ylcarbonylamino)-(2-thienyl)acetonitrile				
<hr/>					
* IICl : hydrochloride.		* IIO : oxalate			

A-1 to A-30 for R⁶ in Table 6 mean the following groups.

5

10

15

20

25

30

35

40

45

50

55

A-1		A-11		A-21	
A-2		A-12		A-22	
A-3		A-13		A-23	
A-4		A-14		A-24	
A-5		A-15		A-25	
A-6		A-16		A-26	
A-7		A-17		A-27	
A-8		A-18		A-28	
A-9		A-19		A-29	
A-10		A-20		A-30	

T a b l e 7

Compound No.	m.p. (°C)	NMR (δ value)
2-1	149~151	6.40-6.55(2H, m), 6.65(1H, d, J=3.0Hz), 6.90(1H, t, J=6.75Hz), 7.50(1H, br), 7.55(1H, d, J=0.9Hz), 7.72(1H, d, J=0.9Hz); 8.12(1H, d, J=6.75Hz), 8.32(1H, d, J=6.75Hz), 11.30(1H, d, J=8.75Hz). (CDCl ₃)
2-2	130~131	2.45(3H, s), 6.50(2H, m), 6.67(1H, d, J=3.0Hz), 6.90(1H, t, J=6.75Hz), 7.40(1H, br), 7.55(1H, d, J=1.5Hz), 8.10-8.30(2H, m), 11.45(1H, d, J=7.5Hz). (CDCl ₃)
2-3	140~141	2.40(3H, s), 6.78(1H, d, J=7.5Hz), 7.15(2H, m), 7.45(1H, m), 7.66(1H, d, J=6.0Hz), 7.88(1H, s), 8.08(1H, d, J=6.75Hz), 8.78(1H, d, J=6.75Hz), 11.28(1H, d, J=7.5Hz). (DMSO-d ₆)
2-4	204~205	2.40(3H, s), 6.55(1H, d, J=7.5Hz), 7.08(1H, t, J=6.75Hz), 7.20-7.70(4H, m), 7.88(1H, s), 8.05(1H, d, J=6.75Hz), 8.75(1H, d, J=6.75Hz), 11.24(1H, d, J=7.5Hz). (DMSO-d ₆)
2-5	102~103	1.30(3H, t, J=7.5Hz), 2.80(2H, q, J=7.5Hz), 6.51-6.70(2H, m), 6.75(1H, d, J=3.0Hz), 7.08(1H, t, J=6.75Hz), 7.83(1H, m), 7.88(1H, s), 8.07(1H, dd, J=6.75Hz, 1.5Hz), 8.78(1H, dd, J=6.75Hz, 1.5Hz), 11.35(1H, d, J=6.75Hz). (DMSO-d ₆)

Table 7 (continued)

Compound No.	m.p. (°C)	NMR (δ value)
2-7	85~87	1.35(6H, d, J=6.0Hz), 3.08(1H, m), 6.45-6.70(2H, m), 6.70(1H, d, J=3.0Hz), 7.03(1H, t, J=6.75Hz), 7.75(1H, m), 7.80(1H, s), 8.06(1H, dd, J=6.75Hz, 1.5Hz), 8.73(1H, dd, J=6.75Hz, 1.5Hz), 11.48(1H, d, J=6.75Hz). (DMSO-d ₆)
2-9	112~114	1.32(9H, s), 6.48-6.65(2H, m), 6.73(1H, d, J=3.0Hz), 7.05(1H, t, J=6.75Hz), 7.78(1H, m), 7.84(1H, s), 8.07(1H, d, J=6.75Hz), 8.74(1H, d, J=6.75Hz), 11.53(1H, d, J=6.75Hz). (DMSO-d ₆)
2-10	142~143	6.50(2H, m), 6.65(1H, d, J=3.75Hz), 7.15(1H, t, J=6.75Hz), 7.45(1H, d, J=1.5Hz), 7.58(1H, s), 8.25(2H, m), 10.95(1H, d, J=7.5Hz). (CDCl ₃)
2-11	157~159	2.45(3H, s), 6.35-6.50(2H, m), 6.65(1H, d, J=3.95Hz), 7.08(1H, t, J=6.75Hz), 7.50(1H, d, J=1.5Hz), 8.10-8.30(2H, m), 11.05(1H, d, J=8.25Hz). (CDCl ₃)
2-15	162~164	2.20(6H, s), 2.40(3H, s), 3.65(2H, s), 6.50(2H, m), 6.68(1H, d, J=3.0Hz), 6.92(1H, t, J=6.75Hz), 7.48(1H, br), 8.12(1H, d, J=6.75Hz), 8.40(1H, d, J=6.75Hz), 11.58(1H, d, J=7.50Hz). (CDCl ₃)
2-17	123~124	2.20(6H, s), 2.40(3H, s), 3.70(2H, s), 6.47(1H, d, J=7.5Hz), 6.95(1H, d, J=6.75Hz), 7.10-7.50(4H, m), 8.20(1H, d, J=6.75Hz), 8.45(1H, d, J=6.75Hz), 11.58(1H, d, J=7.50Hz). (CDCl ₃)
2-19	171~174	

Table 7 (continued)

Compound No.	m.p. (°C)	NMR (δ value)
2-20	184~186	2.35-2.60(4H, m), 2.42(3H, s), 3.55-3.75(4H, m), 3.77(2H, s), 6.50(2H, m), 6.65(1H, d, J=3.0Hz), 6.95(1H, t, J=6.75Hz), 7.55(1H, br), 8.25(1H, d, J=6.75Hz), 8.47(1H, d, J=6.75Hz), 11.45(1H, d, J =7.5Hz). (DMSO-d ₆)
2-24	197~199	6.35-6.50(2H, m), 6.68(1H, d, J=3.75Hz), 6.95 (1H, t, J=6.75Hz), 7.35-7.65(4H, m), 7.70-7.90 (2H, m), 7.92(1H, s), 8.10-8.30(2H, m), 11.56(1H, d, J=7.50Hz). (CDCl ₃)
2-25	187~189	6.76(1H, d, J=6.3Hz), 7.05-7.32(2H, m), 7.33- 7.65(4H, m), 7.70-7.82(1H, m), 7.86-8.02(2H, m), 8.04-8.20(1H, m), 8.59(1H, s), 8.73-8.90(1H, m), 11.34(1H, d, J=6.3Hz). (DMSO-d ₆)
2-26	176~177	6.60(1H, d, J=7.5Hz), 7.14(1H, t, J=6.75Hz), 7.35-7.60(7H, m), 7.80-8.00(2H, m), 8.15(1H, d, J=6.75Hz), 8.67(1H, s), 8.84(1H, d, J=6.75Hz), 11.48(1H, d, J=7.5Hz). (DMSO-d ₆)
2-27	192~193	6.50(1H, d, J=6.6Hz), 7.14(1H, t, J=7.5Hz), 7.36 -7.73(7H, m), 7.80-7.99(2H, m), 8.02-8.20 (1H, m), 8.56(1H, s), 8.72-8.89(1H, m), 11.30(1H, d, J=6.6Hz). (DMSO-d ₆)
2-28	205~206	6.36(1H, d, J=6.6Hz), 6.98-7.53(6H, m), 7.68- 7.95(4H, m), 8.03-8.20(1H, m), 8.42(1H, s), 8.66 -8.80(1H, m), 11.33(1H, d, J=6.6Hz). (CDCl ₃ + DMSO-d ₆)

Table 7 (continued)

Compound No.	m.p.(°C)	NMR(δ value)
2-29	168~170	3.82(3H,s), 6.35(1H,d, J=6.3Hz), 7.03-7.66(8H,m), 7.78-7.95(2H,m), 8.10(1H,dd, J=1.35Hz, 7.5Hz), 8.54(1H,s), 8.78(1H,dd, J=1.35Hz, 7.5Hz), 11.28(1H,d, J=6.3Hz). (DMSO-d ₆)
2-30	181~182	3.80(3H,s), 3.85(3H,s), 6.24(1H,d, J=6.3Hz), 7.04-7.53(7H,m), 7.70-7.91(2H,m), 8.10(1H,dd, J=1.5Hz, 7.2Hz), 8.53(1H,s), 8.79(1H,dd, J=1.5Hz, 7.2Hz), 11.22(1H,d, J=6.3Hz). (DMSO-d ₆)
2-31	203~204	6.48(1H,d, J=6.45Hz), 7.12(1H,t, J=7.2Hz), 7.32-7.65(4H,m), 7.68-8.02(5H,m), 8.10(1H,dd, J=1.35, 7.2Hz), 8.55(1H,s), 8.80(1H,dd, J=1.35, 7.2Hz), 11.25(1H,d, J=6.45Hz). (DMSO-d ₆)
2-32	219~220	6.55(1H,d, J=6.75Hz), 7.15(1H,t, J=7.05Hz), 7.24-7.65(6H,m), 7.88-8.03(2H,m), 8.10(1H,dd, J=1.35, 7.05Hz), 8.53(1H,s), 8.82(1H,dd, J=1.35, 7.05Hz), 11.30(1H,d, J=6.75Hz). (DMSO-d ₆)
2-33	207~208	3.71(3H,s), 6.10-6.26(1H,m), 6.43-6.60(2H,m), 6.89-7.01(1H,m), 7.13(1H,t, J=7.5Hz), 7.31-7.58(3H,m), 7.72-7.92(2H,m), 8.11(1H,dd, J=1.35, 7.5Hz), 8.55(1H,s), 8.79(1H,dd, J=1.35, 7.5Hz), 11.13(1H,d, J=6.45Hz). (DMSO-d ₆)
2-34	174~175	6.28(1H,d, J=7.5Hz), 6.95(1H,t, J=6.9Hz), 7.23-7.84(10H,m), 7.90(1H,s), 8.11-8.32(2H,m), 11.48(1H,d, J=7.5Hz). (CDCl ₃)

Table 7 (continued)

Compound No.	m.p. (°C)	NMR (δ value)
2-35	210~211	6.32(1H, d, J=7.5Hz), 7.03(1H, t, J=7.2Hz), 7.17-7.92(4H, m), 8.16(1H, dd, J=1.35Hz, 7.2Hz), 8.22(1H, s), 8.57(1H, dd, J=1.35Hz, 7.2Hz), 11.46(1H, d, J=7.5Hz). (DMSO-d ₆ +CDCl ₃)
2-36	192~193	6.52(1H, d, J=7.35Hz), 7.05(1H, t, J=7.2Hz), 7.32-7.53(3H, m), 7.61-7.91(4H, m), 7.92-8.22(3H, m), 8.33(1H, s), 8.65(1H, dd, J=1.35Hz, 7.2Hz), 11.41(1H, d, J=7.35Hz). (CDCl ₃ +DMSO-d ₆)
2-37	189~190	2.42(3H, s), 6.34(1H, d, J=6.3Hz), 7.14(1H, t, J=7.2Hz), 7.30-7.68(7H, m), 7.74-7.92(2H, m), 8.11(1H, dd, J=1.35Hz, 7.2Hz), 8.55(1H, s), 8.79(1H, dd, J=1.35Hz, 7.2Hz), 11.25(1H, d, J=6.3Hz). (DMSO-d ₆)
2-40	168~169	1.23(6H, d, J=7.2Hz), 2.12-2.50(1H, m), 5.05(1H, dd, J=6.9Hz, 7.5Hz), 7.16(1H, t, J=6.9Hz), 7.28-7.65(3H, m), 7.90-8.20(3H, m), 8.60(1H, s), 8.82(1H, dd, J=1.35Hz, 6.9Hz), 10.90(1H, d, J=7.5Hz). (DMSO-d ₆)
2-41	181~182	6.37(1H, d, J=7.5Hz), 6.95(1H, t, J=7.2Hz), 6.27-8.37(11H, m), 8.79-8.94(1H, m), 11.97(1H, d, J=7.50Hz). (CDCl ₃)
2-42	213~215	6.58(1H, d, J=6.45Hz), 7.13(1H, t, J=7.2Hz), 7.31-7.71(4H, m), 7.80-8.30(4H, m), 8.55(1H, s), 8.68-8.87(2H, m), 8.96(1H, d, J=2.85Hz), 11.30(1H, d, J=6.45Hz). (CDCl ₃)

Table 7 (Continued)

Compound No.	m.p.(°C)	NMR (δ value)
5	2 45	182~183 3.31(2H,d,J=7.5Hz),5.32-5.62(1H,m),6.93(1H,t,J=6.6Hz),7.23-7.62(8H,m),7.65-8.02(3H,m),8.07-8.36(2H,m),11.03(1H,d,J=8.7Hz). (CDCl ₃)
10	2 46	122~124 3.02(3H,br),6.59(1H,br),6.88-7.12(2H,m),7.18-7.58(5H,m),7.62-7.83(1H,m),7.93-8.25(2H,m),8.35(1H,s),8.60(1H,d,J=7.2Hz). (CD ₃ COCD ₃).
15	2 47	190~192 2.22(3H,s),6.62-6.75(1H,m),6.82(1H,d,J=3.0Hz),7.14(1H,t,J=6.9Hz),7.31-7.63(3H,m),7.76-8.19(4H,m),8.56(1H,s),8.72-8.90(1H,m),11.48(1H,s). (DMSO-d ₆)
20	2 48	192~193 2.42(3H,s),6.20-6.31(1H,m),6.56(1H,d,J=3.3Hz),7.15(1H,t,J=7.2Hz),7.28-7.63(3H,m),7.89-8.06(3H,m),8.12(1H,dd,J=1.35Hz,7.2Hz),8.59(1H,s),8.81(1H,dd,J=1.35Hz,7.2Hz),11.37(1H,d,J=6.9Hz). (DMSO-d ₆)
25	2 49	173~174 4.60(2H,d,J=6.3Hz),7.12(1H,t,J=6.9Hz),7.24-7.62(3H,m),8.00-8.25(3H,m),8.58(1H,s),8.71-8.87(1H,m),10.59(1H,t,J=6.3Hz). (DMSO-d ₆)
30	2 50	109~110 1.27(3H,t,J=7.5Hz),1.75(6H,s),4.23(2H,q,J=7.5Hz),6.92(1H,t,J=6.9Hz),7.23-7.68(3H,m),7.89-8.18(4H,m),8.29-8.50(1H,m),10.95(1H,br). (DMSO-d ₆ , CDCl ₃)
35		
40		
45		
50		
55		

Table 7 (Continued)

Compound No.	m.p.(°C)	NMR (δ value)
2-52	196~197	2.41(3H,s), 6.49(1H,d,J=7.8Hz), 6.80-7.06(2H,m), 7.23-7.57(4H,m), 7.75-7.95(3H,m), 8.07-8.32(2H,m), 11.48(1H,d,J=7.8Hz). (CDCl ₃)
2-53	159~161	6.60(1H,d,J=6.6Hz), 7.12(1H,t,J=6.9Hz), 7.32-7.61(3H,m), 7.69(1H,d,J=9.3Hz), 7.82-8.14(3H,m), 8.22(1H,dd,J=1.2, 9.3Hz), 8.57(1H,s), 8.72-8.89(2H,m), 11.26(1H,d,J=6.6Hz). (DMSO-d ₆)
2-54	175~177	2.54(3H,s), 6.55-6.70(2H,m), 6.75(1H,d,J=3.0Hz), 7.20(1H,t,J=6.75Hz), 7.30-7.50(3H,m), 7.80-8.00(2H,m), 8.15(1H,d,J=6.75Hz), 8.45(1H,s), 8.85(1H,d,J=6.75Hz), 11.35(1H,d,J=7.50Hz). (DMSO-d ₆)
2-55	175~176	2.45(3H,s), 6.75(1H,d,J=7.5Hz), 7.10-8.30(8H,m), 8.42(1H,s), 8.86(1H,d,J=6.75Hz), 11.27(1H,d,J=7.5Hz). (DMSO-d ₆)
2-56	119~120	2.45(3H,s), 6.53(1H,d,J=7.5Hz), 7.10-7.90(9H,m), 8.15(1H,d,J=6.75Hz), 8.45(1H,s), 8.86(1H,d,J=6.75Hz), 11.28(1H,d,J=7.5Hz). (DMSO-d ₆)
2-57	214~216	2.40(3H,s), 6.50-6.70(2H,m), 6.82(1H,d,J=3.0Hz), 7.00-7.55(3H,m), 7.65-7.95(3H,m), 8.12(1H,d,J=6.75Hz), 8.55(1H,s), 8.80(1H,d,J=6.75Hz), 11.45(1H,d,J=6.75Hz). (DMSO-d ₆)

Table 7 (Continued)

Compound No.	m.p.(°C)	NMR (δ value)
2-58	198~200	2.35(3H,s), 6.60-6.75(2H,m), 6.80(1H,d, J=3.0Hz), 7.15(1H,t, J=6.75Hz), 7.32(2H,d, J=8.35Hz), 7.75-8.00(3H,m), 8.10(1H,d, J=6.75Hz), 8.54(1H,s), 8.80(1H,d, J=6.75Hz), 11.52(1H,d, J=6.75Hz). (DMSO-d ₆)
2-59	173~175	2.39(3H,s), 2.50(3H,s), 6.40(1H,d, J=6.6Hz), 6.41-6.58(2H,m), 6.72(1H,d, J=3.0Hz), 7.08(1H,t, J=6.0Hz), 7.18(1H,m), 7.52-7.72(2H,m), 8.05(1H,s), 8.27(1H,dd, J=7.5Hz, 0.3Hz), 8.59(1H,dd, J=7.5Hz, 0.3Hz), 11.48(1H,d, J=6.6Hz). (CDCl ₃)
2-60	134~135	2.34(3H,s), 2.47(3H,s), 6.53(1H,d, J=7.5Hz), 6.90-7.25(4H,m), 7.31-7.48(2H,m), 7.80(1H,s), 7.18-7.40(2H,m), 11.56(1H,d, J=7.5Hz). (CDCl ₃)
2-63	167~169	4.01(3H,s), 6.55-6.70(2H,m), 6.80(1H,d, J=3.0Hz), 7.00-7.50(4H,m), 7.95(1H,br), 8.00-8.25(2H,m), 8.68(1H,s), 8.87(1H,t, J=6.75Hz), 11.51(1H,d, J=6.0Hz). (DMSO-d ₆)
2-64	167~169	3.82(3H,s), 6.55-6.70(2H,m), 6.82(1H,d, J=3.0Hz), 6.85-7.60(5H,m), 7.89(1H,m), 8.13(1H,d, J=6.75Hz), 8.58(1H,s), 8.80(1H,d, J=6.75Hz), 11.42(1H,d, J=6.75Hz). (DMSO-d ₆)
2-65	179~180	3.85(3H,s), 6.55-6.70(2H,m), 6.70(1H,d, J=3.0Hz), 7.00-7.25(3H,m), 7.85-8.05(3H,m), 8.12(1H,d, J=6.75Hz), 8.45(1H,s), 8.80(1H,d, J=6.75Hz), 11.45(1H,d, J=6.75Hz). (DMSO-d ₆)

Table 7 (Continued)

Compound No.	m.p. (°C)	NMR (δ value)
2-66	186~188	3.84(6H, s), 6.58-6.71(2H, m), 6.80(1H, d, J=3.0 Hz), 7.43-7.68(2H, m), 7.10(1H, d, J=7.5 Hz), 8.10(1H, d, J=6.75 Hz), 8.50(1H, s), 8.80(1H, d, J=6.75 Hz), 11.40(1H, d, J=7.5 Hz). (DMSO-d ₆)
2-67	140~141	3.83(3H, s), 3.90(3H, s), 6.40(1H, d, J=7.5 Hz), 6.83-7.20(3H, m), 7.25-7.60(5H, m), 7.88(1H, s), 8.18(1H, dd, J=6.0 Hz, 1.5 Hz), 8.25(1H, dd, J=6.0 Hz, 1.5 Hz), 11.55(1H, d, J=7.5 Hz). (CDCl ₃)
2-68	176~178	6.55-6.70(2H, m), 6.78(1H, d, J=3.0 Hz), 7.18(1H, t, J=6.75 Hz), 7.34-7.66(3H, m), 7.78(1H, br), 8.10-8.30(2H, m), 8.76(1H, s), 8.88(1H, d, J=6.75 Hz), 11.30(1H, d, J=6.75 Hz). (DMSO-d ₆)
2-69	235~237	6.55-6.75(2H, m), 6.82(1H, d, J=3.0 Hz), 7.20(1H, t, J=6.75 Hz), 7.35-7.70(2H, m), 7.88-8.30(4H, m), 8.66(1H, s), 8.84(1H, d, J=6.75 Hz), 11.32(1H, d, J=6.75 Hz). (DMSO-d ₆)
2-70	222~224	6.55-6.70(2H, m), 6.83(1H, d, J=3.0 Hz), 7.18(1H, t, J=6.75 Hz), 7.53(2H, d, J=8.25 Hz), 7.90-8.20(4H, m), 8.61(1H, s), 8.82(1H, d, J=6.75 Hz), 11.38(1H, d, J=6.75 Hz). (DMSO-d ₆)
2-71	233~234	6.55-6.75(2H, m), 6.82(1H, d, J=3.0 Hz), 7.16(1H, t, J=6.75 Hz), 7.78(2H, d, J=8.25 Hz), 7.90(2H, d, J=8.25 Hz), 7.98(1H, m), 8.15(1H, d, J=6.75 Hz), 8.60(1H, s), 8.83(1H, d, J=6.75 Hz), 11.32(1H, d, J=6.75 Hz). (DMSO-d ₆)

Table 7 (Continued)

Compound No.	m.p.(°C)	NMR (δ value)
2-72	249~251	6.55-6.70(2H,m), 6.78(1H,d, J=3.0Hz), 7.19 (1H,t, J=6.75Hz), 7.95-8.45(6H,m), 8.75-8.90 (2H,m), 11.25(1H,d, J=6.75Hz). (DMSO-d ₆)
2-73	208~210	6.65(2H,m), 6.83(1H,d, J=3.0Hz), 7.21(1H,t, J=6.75Hz), 7.30-7.60(3H,m), 7.95(1H,m), 8.05-8.35(2H,m), 8.54(1H,d, J=4.5Hz), 8.90(1H,d, J=6.75Hz), 11.46(1H,d, J=7.5Hz). (DMSO-d ₆)
2-78	173~175	2.26(6H,s), 3.92(2H,s), 6.53(1H,d, J=8.1Hz), 6.90-7.11(2H,m), 7.32-7.55(4H,m), 7.63-7.84(2H,m), 8.28(1H,dd, J=7.5Hz, 0.75Hz), 8.63(1H,dd, J=7.5Hz, 0.75Hz), 11.65(1H,d, J=8.1Hz). (CDCl ₃)

Table 7 (continued)

Compound No.	m.p. (°C)	NMR (δ value)
2-79	176~177	2.26(6H, s), 3.93(2H, s), 6.36(1H, d, J=8.1Hz), 6.91-7.34(2H, m), 7.43-7.60(6H, m), 7.66-7.85 (2H, m), 8.21-8.38(1H, m), 8.57-8.73(1H, m), 11.65(1H, d, J=8.1Hz). (CDCl ₃)
2-80	~125	
2-81	173	6.58-6.70(2H, m), 6.80(1H, d, J=3.3Hz), 7.32(1H, t, J=6.9Hz), 7.40-7.73(3H, m), 7.88-8.29(4H, m), 8.65(1H, dd, J=1.5Hz, 6.9Hz), 11.05(1H, d, J=7.2 Hz). (DMSO-d ₆)
2-82	169~171	2.70(3H, s), 6.48(1H, d, J=6.3Hz), 7.18(1H, t, J= 6.9Hz), 7.28-7.86(9H, m), 8.12(1H, dd, J=1.5Hz, 6.9Hz), 8.62(1H, dd, J=1.5Hz, 6.9Hz), 11.39(1H, d, J=6.3Hz). (DMSO-d ₆)
2-83	129~131	6.32(1H, d, J=6.3Hz), 6.91(1H, t, J=6.3Hz), 7.15 -7.75(14H, m), 8.05(1H, dd, J=6.3Hz, 1.5Hz), 8.25(1H, dd, J=6.3Hz, 1.5Hz), 11.68(1H, d, J=6.3 Hz). (CDCl ₃)
2-92	145~146	6.31(1H, d, J=8.4Hz), 7.12(1H, t, J=6.5Hz), 7.20 -7.55(4H, m), 7.98(1H, s), 7.30(1H, dd, J=7.5Hz, 1.5Hz), 7.35(1H, dd, J=7.5Hz, 1.5Hz), 10.85(1H, d, J=8.4Hz). (CDCl ₃)
2-104	221~222	6.15-6.70(2H, m), 6.70-6.95(2H, m), 7.20(1H, t, J=6.5Hz), 7.80-7.95(1H, m), 8.27(1H, dd, J=7.5 Hz, 1.5Hz), 8.41(1H, s), 8.83(1H, dd, J=7.5Hz, 1.5Hz), 11.50(1H, d, J=6.0Hz). (DMSO-d ₆)

Table 7 (continued)

Compound No.	m.p. (°C)	NMR (δ value)
2-109	197~198	2.42(3H,s), 6.29(1H,d, J=8.4Hz), 7.15-7.55(7H,m), 7.70-7.85(2H,m), 7.80(1H,s), 8.05(2H,s), 11.53(1H,d, J=8.4Hz). (CDCl ₃)
2-112	206~207	2.57(3H,s), 2.71(3H,s), 6.32(1H,d, J=6.0Hz), 6.50(1H,d, J=6.3Hz), 6.54(1H,d, J=6.3Hz), 6.67(1H,d, J=3.0Hz), 7.31-7.52(3H,m), 7.55(1H,m), 7.62(1H,s), 7.71-7.92(2H,m), 12.30(1H,d, J=6.0Hz). (CDCl ₃)
2-114	119~121	4.22(2H,s), 6.38(1H,d, J=9.0Hz), 6.92(1H,t, J=8.0Hz), 7.10-7.50(9H,m), 7.55(1H,s), 8.19(2H,d, J=6.3Hz), 11.23(1H,d, J=9.0Hz). (CDCl ₃)
2-115	138~139	5.28(2H,s), 6.44(1H,d, J=9.0Hz), 6.95(1H,t, J=8.0Hz), 7.00-7.50(9H,m), 7.70(1H,s), 8.25(2H,d, J=6.3Hz), 11.21(1H,d, J=9.0Hz). (CDCl ₃)
2-119	127~128	3.50(3H,s), 4.65(2H,s), 6.33-6.50(2H,m), 6.93(1H,t, J=6.3Hz), 7.49(1H,m), 7.62(1H,s), 8.15-8.32(2H,m), 11.25(1H,d, J=7.5Hz). (CDCl ₃)
2-120	108~109	2.31-2.57(4H,m), 3.47(3H,s), 3.55-3.75(4H,m), 3.90(2H,s), 4.63(2H,s), 6.37-6.53(2H,m), 6.93(1H,t, J=6.3Hz), 7.48(1H,m), 8.23(1H,dd, J=7.5Hz, 1.5Hz), 8.51(1H,dd, J=7.5Hz, 1.5Hz), 11.32(1H,d, J=7.5Hz). (CDCl ₃)
2-121	165~166	2.17(3H,s), 3.80(2H,s), 6.33-6.50(2H,m), 6.60-6.73(1H,m), 6.95(1H,d, J=6.0Hz), 7.50(1H,m), 7.60(1H,s), 8.12-8.30(2H,m), 11.27(1H,d, J=7.5Hz). (CDCl ₃)

Table 7 (continued)

Compound No.	m.p.(°C)	NMR (δ value)
2-122	214~216	2.61(3H, d, J=3.0Hz), 4.20(2H, s), 6.33-6.51(2H, m), 6.58-6.75(1H, m), 7.08(1H, t, J=6.0Hz), 7.60(1H, m), 8.00(1H, s), 8.18(1H, dd, J=6.0Hz, 1.5Hz), 8.60(1H, dd, J=6.0Hz, 1.5Hz), 11.08(1H, d, J=6.3Hz). (CDCl ₃ +DMSO-d ₆)
2-123	117~118	2.19(3H, s), 2.25(6H, s), 3.72(2H, s), 3.83(2H, s), 6.32-6.48(2H, m), 6.65(1H, d, J=3.0Hz), 6.98(1H, d, J=6.0Hz), 7.50(1H, m), 7.72(1H, dd, J=6.0Hz, 1.5Hz), 8.50(1H, dd, J=6.0Hz, 1.5Hz), 11.40(1H, d, J=6.6Hz). (CDCl ₃)
2-127	169~171	3.38(3H, br), 3.55(3H, br), 4.75(2H, s), 6.36-6.51(2H, m), 6.59-6.70(1H, m), 6.93(1H, t, J=6.0Hz), 7.45-7.55(1H, m), 7.78(1H, s), 8.28(1H, d, J=7.5Hz), 11.21(1H, br). (CDCl ₃)
2-128	184~186	4.73(2H, s), 6.32-6.50(2H, m), 6.65(1H, d, J=3.0Hz), 6.98(1H, d, J=6.0Hz), 7.50(1H, m), 7.72(1H, s), 8.23(1H, d, J=7.5Hz), 11.10(1H, br). (CDCl ₃)
2-134	120~125 (hydrochloride)	5.70(1H, br), 6.50(1H, d, J=6.3Hz), 7.16-7.82(8H, m), 7.82-8.10(2H, m), 8.16-8.32(1H, m), 8.68(1H, s), 8.82-9.00(1H, m), 11.21(1H, d, J=6.3Hz). (DMSO-d ₆)
2-135	112~115	2.40(3H, s), 6.35(2H, m), 6.63(1H, d, J=3.0Hz), 7.20-7.60(8H, m), 8.55(1H, d, J=6.75Hz), 9.80(1H, d, J=6.75Hz), 9.82(1H, s), 11.07(1H, d, J=8.5Hz). (CDCl ₃)

Table 7 (continued)

Compound No.	m.p.(°C)	NMR(δ value)
2-136	171~172	6.50(1H,d,J=7.5Hz), 7.10-7.75(8H,m), 7.95(1H,m), 8.18(1H,d,J=6.75Hz), 8.50 (1H,d,J=4.5Hz), 8.90(1H,d,J=6.75Hz), 11.20(1H,d,J=7.5Hz). (DMSO-d ₆)
2-137	190~191	6.75(1H,d,J=7.5Hz), 7.05-7.55(6H,m), 7.72(1H,d,J=6.0Hz), 7.95-8.25(1H,m), 8.15(1H,d,J=6.75Hz), 8.48(1H,d,J=4.5Hz), 8.88(1H,d,J=6.75Hz), 11.25(1H,d,J=7.5Hz). (DMSO-d ₆)
2-138	192~193	3.83(3H,s), 3.91(3H,s), 6.58(1H,d,J=7.5Hz), 6.80-7.15(3H,m), 7.82(1H,s), 8.23(2H,m), 11.58(1H,d,J=7.5Hz). (CDCl ₃)
2-139	184~185	2.38(6H,s), 2.43(3H,s), 6.32(1H,d,J=7.5Hz), 6.32-6.49(2H,m), 6.61(1H,m), 6.95-7.20(2H,m), 7.50(1H,m), 6.62(2H,m), 8.05(1H,m), 11.50(1H,d,J=7.5Hz). (CDCl ₃)
2-140	215~217	6.77(1H,d,J=7.5Hz), 7.08-7.45(4H,m), 7.52(1H,d,J=3.0Hz), 7.77(1H,dd,J=6.0,3.0Hz), 7.85-8.20(3H,m), 8.58(1H,s), 8.80(1H,d,J=6.75Hz), 11.25(1H,d,J=7.5Hz). (DMSO-d ₆)
2-141	220~222	6.75(1H,d,J=7.5Hz), 7.10-7.50(5H,m), 7.77(1H,dd,J=3.75,5.25Hz), 7.90-8.35(2H,m), 8.50(1H,d,J=4.0Hz), 8.90(1H,d,J=6.75Hz), 11.13(1H,d,J=7.5Hz). (DMSO-d ₆)
2-142	154~156	6.58(1H,d,J=7.5Hz), 6.80-7.50(7H,m), 8.05(1H,t,J=1.5Hz), 8.15-8.40(2H,m), 11.56(1H,d,J=7.5Hz). (CDCl ₃)

Table 7 (continued)

Compound No.	m.p.(°C)	NMR (δ value)
2-143	165~166	5.10(2H,s), 6.52(1H,d,J=7.5Hz), 7.00-7.21(2H,m), 7.40-7.60(4H,m), 7.72-7.88(2H,m), 8.28(1H,m), 8.68(1H,m), 11.63(1H,d,J=7.5Hz). (CDCl ₃)
2-144	181~182	3.00(6H,s), 6.55(1H,d,J=7.5Hz), 6.73(2H,d,J=9.0Hz), 6.82-7.15(2H,m), 7.20(2H,d,J=9.0Hz), 7.32-7.50(2H,m), 7.74(1H,s), 8.15(2H,m), 11.70(1H,d,J=7.5Hz). (CDCl ₃)
2-145	202~204	6.70-6.85(1H,m), 7.03-7.19(1H,m), 7.38-7.50(1H,m), 7.60-7.83(2H,m), 8.08-8.63(5H,m), 9.67(1H,dd,J=1.35,7.35Hz), 10.49(1H,d,J=6.75Hz). (DMSO-d ₆)
2-146	182~184 (decomp.)	6.35(1H,d,J=7.65Hz), 6.99-7.16(1H,m), 7.21-7.33(1H,m), 7.36-7.66(5H,m), 7.70-7.92(2H,m), 8.58(1H,dd,J=1.35,7.5Hz), 9.83(1H,dd,J=1.35,7.2Hz), 10.15(1H,s), 11.19(1H,d,J=7.65Hz). (CDCl ₃)
2-147	162~164	6.58(1H,d,J=7.5Hz), 6.80-7.50(7H,m), 8.05(1H,d,J=1.5Hz), 8.15-8.40(2H,m), 11.56(1H,d,J=7.5Hz). (CDCl ₃)
2-148	177~179	6.57(1H,d,J=7.8Hz), 6.99-7.12(1H,m), 7.15-7.62(11H,m), 7.68-7.86(2H,m), 8.50(1H,dd,J=1.35,7.5Hz), 8.88(1H,s), 10.30(1H,dd,J=1.35,7.5Hz), 11.42(1H,d,J=7.8Hz). (CDCl ₃)

Table 7 (continued)

Compound No. m.p.(°C)		NMR(δ value)
2-149	208~210	2.63(3H,s), 6.71(1H,d,J=7.5Hz), 7.00-7.18(1H,m), 7.38-7.50(1H,m), 7.56-7.82(3H,m), 8.14(1H,dd,J=1.35, 8.25Hz), 8.48-8.63(2H,m), 9.58-9.73(1H,m), 10.51(1H,d,J=7.5Hz). (DMSO-d ₆)
2-150	149~151	2.43(3H,s), 6.60(1H,d,J=7.5Hz), 7.22(1H,t,J=6.75Hz), 7.40-7.80(5H,m), 7.94(1H,s), 8.15(1H,dd,J=6.75, 1.50Hz), 8.85(1H,dd,J=6.75, 1.50Hz), 11.28(1H,d,J=7.5Hz). (DMSO-d ₆)
2-151	134~135	1.30(3H,t,J=7.0Hz), 2.80(2H,q,J=7.0Hz), 6.40(1H,d,J=7.5Hz), 6.93(1H,t,J=6.75Hz), 7.30-7.75(6H,m), 8.08-8.30(2H,m), 11.52(1H,d,J=7.5Hz). (CDCl ₃)
2-152	141~143	2.45(3H,s), 6.42(1H,d,J=7.5Hz), 7.05-7.38(4H,m), 7.40-7.85(6H,m), 8.13(1H,d,J=6.75Hz), 8.40(1H,s), 8.85(1H,d,J=6.75Hz), 11.18(1H,d,J=7.5Hz). (DMSO-d ₆)
2-153	235~237	6.40(1H,d,J=7.5Hz), 7.00-7.40(3H,m), 7.45-8.00(7H,m), 8.12(1H,d,J=6.75Hz), 8.50(1H,s), 8.80(1H,d,J=6.75Hz), 11.19(1H,d,J=7.5Hz). (DMSO-d ₆)
2-154		2.85(3H,s), 6.55(1H,d,J=7.5Hz), 7.09(1H,m), 7.20-7.55(3H,m), 8.60(1H,d,J=6.75Hz), 9.60(1H,d,J=6.75Hz), 10.85(1H,d,J=7.5Hz). (CDCl ₃)

Table 7 (continued)

Compound No.	m.p.(°C)	NMR(δ value)
2-155	163~165	6.53(1H,d,J=7.5Hz), 6.95(1H,t,J=6.75 Hz), 7.00-7.30(1H,m), 7.32-7.76(1H,m), 7.92(1H,s), 8.21(2H,m), 11.57(1H,d,J=7.5Hz). (CDCl ₃)
2-156	111~115 (hydrochloride)	6.75(1H,d,J=6.75Hz), 6.68-7.11(1H,br), 7.11-7.82(7H,m), 7.88-8.11(2H,m), 8.23(1H,dd,J=1.35,7.5Hz), 8.68(1H,s), 8.92(1H,dd,J=1.35,7.5Hz), 11.26(1H,d,J=6.75Hz). (DMSOd ₆)
2-157	174~176	6.52(1H,d,J=7.5Hz), 7.00-7.19(2H,m), 7.36-7.58(5H,m), 7.98-8.16(2H,m), 8.25-8.48(2H,m), 11.27(1H,d,J=7.5Hz). (CDCl ₃)
2-158	167~168	6.57(1H,d,J=8.4Hz), 7.02-7.18(1H,m), 7.38-7.70(3H,m), 8.63(1H,dd,J=1.35,7.5Hz), 8.66(1H,s), 9.61(1H,dd,J=1.35,7.5Hz), 10.70(1H,d,J=8.4Hz). (CDCl ₃ , DMSOd ₆)
2-159	238~240 (decomp.)	2.58(3H,s), 6.68(1H,d,J=6.9Hz), 7.03-7.25(2H,m), 7.46-7.72(3H,m), 8.01-8.24(2H,m), 8.45-8.52(1H,m), 8.63(1H,s), 8.70-8.86(1H,m), 11.11(1H,d,J=6.9Hz). (DMSOd ₆)
2-160	219~220 (decomp.)	6.67(1H,d,J=7.2Hz), 6.92-7.10(1H,m), 7.27-7.39(1H,m), 7.49-7.64(1H,m), 7.68-8.02(3H,m), 8.19-8.38(1H,m), 8.52(1H,dd,J=1.35,7.35Hz), 9.62(1H,dd,J=1.35,7.35Hz), 10.37(1H,d,J=7.2Hz). (DMSOd ₆)

Table 7 (continued)

Compound No.	m.p.(°C)	NMR(δ value)
2-161	265 (decomp.)	6.72(1H,d,J=6.6Hz), 7.10-7.57(3H,m), 7.66- 8.01(5H,m), 8.23(1H,dd,J=1.35, 7.5Hz), 8.70(1H,s), 8.91(1H,dd,J=1.35, 7.5Hz), 11.09(1H,d,J=6.6Hz), 13.82(1H,s). (DMSO-d ₆)
2-162	178~179	6.48(1H,d,J=6.5Hz), 7.00(1H,t,J=6.5Hz), 7.00-7.20(1H,m), 8.10(1H,m)8.20-8.35(2H,m), 8.41(1H,s), 11.18(1H,d,J=6.5Hz). (DMSO-d ₆)
2-163	212~213	3.71(3H,s), 3.97(3H,s), 6.58(1H,d,J=6.5Hz), 6.85-7.25(4H,m), 7.45-7.75(3H,m), 8.21(1H, d,J=7.5Hz), 8.40(1H,s), 8.52(1H,d,J=7.5Hz), 11.50(1H,d,J=6.5Hz). (DMSO-d ₆)
2-164	amorphous (triethylamine)	1.36(9H,t,J=7.5Hz), 2.65(3H,s), 3.17(6H,q, J=7.5Hz), 6.56(1H,d,J=7.8Hz), 6.92-7.18(2H, m), 7.28-7.50(2H,m), 8.28(1H,dd,J=1.35, 7.5Hz), 9.00(1H,dd,J=1.35, 7.5Hz), 11.44(1H, d,J=7.8Hz). (CDCl ₃)
2-165	150~152	2.53(3H,s), 2.69(3H,s), 6.55(1H,d,J=7.5Hz), 7.01-7.32(2H,m), 7.36-7.81(3H,m), 8.32- 8.50(1H,m), 8.97(1H,dd,J=1.35, 6.6Hz), 11.19(1H,d,J=7.5Hz). (DMSO-d ₆ +CDCl ₃)
2-166	183~186 (p-toluenesulfonate)	2.29(3H,s), 6.00-6.39(1H,br), 6.73(1H,d,J= 7.2Hz), 7.03-7.36(5H,m), 7.40-7.62(6H,m), 7.67-7.78(1H,m), 7.85-8.01(2H,m), 8.19(1H, dd,J=1.35, 7.5Hz), 8.62(1H,s), 8.87(1H,dd, J=1.35, 7.5Hz), 11.19(1H,d,J=7.2Hz). (DMSO-d ₆)

Table 7 (continued)

Compound No.	m.p.(°C)	NMR(δ value)
2-167	195~196	6.73(1H,d,J=7.5Hz), 7.03-7.33(2H,m), 7.36-7.48(1H,m), 7.65(1H,dd,J=1.35, 5.4Hz), 8.17(1H,dd,J=1.35, 7.8Hz), 8.25(1H,s), 8.78(1H,dd,J=1.35, 7.2Hz), 10.42(1H,d,J=7.5Hz). (DMSO-d ₆)
2-168	253~256	6.55-6.75(3H,m), 7.20(1H,t,J=6.75Hz), 8.00-8.50(5H,m), 8.75-8.90(2H,m), 11.25(1H,d,J=6.0Hz). (DMSO-d ₆)
2-169	196~198	1.15(3H,t,J=7.0Hz), 2.80(3H,s), 3.67(2H,q,J=7.0Hz), 5.74(1H,d,J=9.0Hz), 7.40-7.90(2H,m), 7.60(1H,t,J=6.75Hz), 8.50(1H,d,J=6.75Hz), 9.60(1H,d,J=6.75Hz), 10.50(1H,d,J=9.0Hz). (DMSO-d ₆)
2-170	185~187	2.72(3H,s), 6.52(1H,d,J=7.5Hz), 7.40-7.75(6H,m), 8.50(1H,d,J=6.75Hz), 10.72(1H,d,J=7.5Hz). (DMSO-d ₆)
2-171	222~223	6.75(1H,d,J=6.5Hz), 7.10-7.30(2H,m), 7.55(1H,m), 7.65-8.80(2H,m), 7.95(1H,d,J=3.5Hz), 8.20(1H,d,J=6.75Hz), 8.64(1H,s), 8.85(1H,d,J=6.75Hz), 10.98(1H,d,J=6.5Hz). (DMSO-d ₆)
2-172	118~120	5.05(2H,br), 6.54(1H,d,J=7.2Hz), 7.21-7.85(6H,m), 8.16-8.31(1H,m), 8.72-8.98(2H,m), 10.48(1H,d,J=7.2Hz). (DMSO-d ₆)
2-173	178~180	6.78(1H,d,J=6.5Hz), 7.20(1H,t,J=6.5Hz), (hydrochloride) 7.30-7.82(7H,m), 8.10(1H,m), 8.56(1H,s), 8.84(1H,m), 11.18(1H,d,J=6.5Hz). (DMSO-d ₆)

Table 7 (continued)

Compound No.	m.p.(°C)	NMR (δ value)
2-174	188~190 (hydrochloride)	6.73(1H,d,J=6.5Hz), 6.95(1H,t,J=6.5Hz), 7.00-7.98(8H,m), 8.20(1H,m), 8.25(1H,s), 8.61(1H,m), 11.25(1H,d,J=6.5Hz). (DMSO-d ₆)
2-175	158~159	4.00(3H,s), 6.75(1H,d,J=7.5Hz), 6.93 7.45(5H,m), 7.55(1H,m), 7.75(1H,m), 7.95 8.30(2H,m), 8.58(1H,s), 8.85(1H,d, J=6.75Hz), 11.45(1H,d,J=7.5Hz). (DMSO-d ₆)
2-176	160~161	3.75(3H,s), 6.78(1H,d,J=7.5Hz), 6.85 7.63(7H,m), 7.72(1H,dd,J=6.0,1.0Hz), 8.17(1H,dd,J=6.75,1.5Hz), 8.59(1H,s), 8.82(1H,dd,6.75,1.5Hz), 11.35(1H,d,J= 7.5Hz). (DMSO-d ₆)
2-177	229~230	3.86(3H,s), 6.74(1H,d,J=7.5Hz), 6.90 7.25(3H,m), 7.50(1H,m), 7.72(1H,dd,J= 6.0,1.0Hz), 7.88(2H,d,J=8.5Hz), 8.12 (1H,dd,J=6.75,1.5Hz), 8.42(1H,s), 8.88 (1H,dd,J=6.75,1.5Hz), 11.40(1H,d,J= 7.5Hz). (DMSO-d ₆)
2-178	172~173	6.78(1H,d,J=7.5Hz), 7.15-7.85(6H,m), 8.00-8.35(3H,m), 8.85(1H,s), 8.95(1H,d, J=6.75Hz), 11.25(1H,d,J=7.5Hz). (DMSO-d ₆)
2-179	225~226	6.75(1H,d,J=7.5Hz), 7.05-7.30(2H,m), 7.40-7.60(3H,m), 7.65-8.05(3H,m), 8.18 (1H,d,J=6.75Hz), 8.65(1H,s), 8.81(1H,d, J=6.75Hz), 11.23(1H,d,J=7.5Hz). (DMSO-d ₆)

Table 7 (continued)

Compound No.	m.p.(°C)	NMR(δ value)
2-180	228~229	6.75(1H,d,J=7.5Hz), 7.00-7.30(2H,m), 7.40-7.65(2H,m), 7.77(1H,dd,J=6.0, 1.0Hz), 7.95(2H,d,J=8.5Hz), 8.15(1H,dd, J=6.75,1.5Hz), 8.63(1H,s), 8.84(1H,dd, J=6.75,1.5Hz), 11.35(1H,d,J=7.5Hz). (DMSO-d ₆)
2-181	179~180	2.37(3H,s), 2.48(3H,s), 6.67(1H,d,J= 7.5Hz), 6.91-7.18(4H,m), 7.33-7.45(2H, m), 7.60(1H,d,J=9.0Hz), 7.78(1H,s), 8.28-8.40(2H,m), 11.53(1H,d,J=7.5Hz). (CDCl ₃)
2-182	193~195	2.30(6H,s), 6.50(1H,d,J=7.5Hz), 6.91 (1H,t,J=6.0Hz), 7.03-7.30(3H,m), 7.39- 7.51(2H,m), 7.53-7.65(1H,m), 7.85(1H,s) , 8.10-8.28(2H,m), 11.60(1H,d,J=7.5Hz). (CDCl ₃)
2-183	205~207	2.50(6H,br), 6.75(1H,d,J=8.5Hz), 7.00- 7.30(4H,m), 7.38-7.53(1H,m), 7.65-7.85 (2H,m), 8.14(1H,d,J=6.75Hz), 8.35(1H,s) , 8.85(1H,d,J=6.75Hz), 11.28(1H,d,J= 8.5Hz). (DMSO-d ₆)
2-184	103~104	1.34(9H,s), 2.50(3H,s), 6.60(1H,d,J= 8.5Hz), 6.80-7.15(2H,m), 7.20-7.45(4H, m), 7.60-7.85(2H,m), 8.18(1H,d,J= 6.75Hz), 8.30(1H,d,J=6.75Hz), 11.59(1H, d,J=8.5Hz). (CDCl ₃)
2-185	129~130	1.32(9H,s), 2.45(3H,s), 6.65(1H,d,J= 8.5Hz), 6.80-7.20(2H,m), 7.21-7.51(4H, m), 7.75-7.90(2H,m), 8.21(1H,d,J= 6.75Hz), 8.32(1H,d,J=6.75Hz), 11.55(1H, d,J=8.5Hz). (CDCl ₃)

Table 7 (continued)

Compound No.	m.p. (°C)	NMR (δ value)
2-186	159~160	2.35(3H,s), 6.75(1H,d,J=8.5Hz), 7.08-7.30(3H,m), 7.38-7.56(2H,m), 7.72(1H,d,J=4.5Hz), 7.90(1H,m), 8.18(1H,d,J=6.75Hz), 8.78(1H,s), 8.92(1H,d,J=6.75Hz), 11.18(1H,d,J=8.5Hz). (DMSO-d ₆)
2-187	184~185	2.40(3H,s), 6.75(1H,d,J=7.5Hz), 7.00-7.90(8H,m), 8.18(1H,d,J=6.75Hz), 8.58(1H,s), 8.85(1H,d,J=6.75Hz), 11.43(1H,d,J=7.5Hz). (DMSO-d ₆)
2-188	218~220	2.35(3H,s), 6.76(1H,d,J=7.5Hz), 7.00-7.40(4H,m), 7.54(1H,m), 7.65-7.95(3H,m), 8.13(1H,dd,J=6.75,1.5Hz), 8.50(1H,s), 8.83(1H,dd,J=6.75,1.5Hz), 11.38(1H,d,J=7.5Hz). (DMSO-d ₆)
2-189	186~188 (decomp.)	2.67(3H,s), 6.61(1H,d,J=7.8Hz), 6.92-7.16(2H,m), 7.33-7.67(6H,m), 7.86-8.07(2H,m), 8.23(1H,dd,J=1.35,6.45Hz), 8.61(1H,dd,J=1.35,6.45Hz), 8.71(1H,s), 11.33(1H,d,J=7.8Hz). (CDCl ₃)
2-190	132~134	6.49(1H,d,J=7.8Hz), 6.90-7.50(10H,m), 8.10-8.30(2H,m), 10.71(1H,d,J=7.8Hz). (CDCl ₃)
2-191	155~157	6.71(1H,d,J=7.5Hz), 6.99-7.19(2H,m), 7.20-7.53(6H,m), 7.60(1H,dd,J=1.35,5.1Hz), 8.13(1H,dd,J=1.35,7.5Hz), 8.38(1H,s), 8.88(1H,dd,J=1.35,6.75Hz), 10.80(1H,d,J=7.5Hz). (DMSO-d ₆)

Table 7 (continued)

Compound No.	m.p.(°C)	NMR (δ value)
2-194	235~237	6.75(1H, d, J=6.3Hz), 7.05-7.34(2H, m), 7.50-7.60(3H, m), 7.78-8.07(5H, m), 8.15 (1H, dd, J=1.5, 6.45Hz), 8.39-8.47(1H, m), 8.69(1H, s), 8.83(1H, dd, J=1.5, 6.45Hz), 11.38(1H, d, J=6.3Hz). (DMSO-d ₆)
2-195	170~172	2.37(3H, s), 3.02(2H, br), 6.60(1H, d, J= 8.1Hz), 6.70-7.14(2H, m), 7.35-7.51(2H, m), 8.00-8.29(2H, m), 11.49(1H, d, J= 8.1Hz). (CDCl ₃)
2-196	187~189	2.20-2.45(12H, m), 6.74(1H, d, J=8.5Hz), 7.00-7.28(2H, m), 7.35(1H, s), 7.45(1H, d, J=3.0Hz), 7.63(1H, d, J=6.0Hz), 8.05- 8.28(2H, m), 8.82(1H, d, J=6.75Hz), 11.40 (1H, d, J=8.5Hz). (DMSO-d ₆)
2-197	118~120	1.35(3H, t, J=7.0Hz), 2.76(2H, q, J=7.0Hz) , 6.62(1H, d, J=7.5Hz), 6.85-7.10(2H, m), 7.35(1H, m), 7.65(1H, d, J=4.5Hz), 7.75(1 H, s), 8.98(1H, d, J=6.75, 1.5Hz), 8.62(1H, d, J=6.75Hz), 11.27(1H, d, J=7.5Hz). (DMSO-d ₆)
2-200	195~196	1.23(3H, t, J=7.0Hz), 2.66(2H, q, J=7.0Hz) , 6.71(1H, d, J=8.5Hz), 7.00-7.40(4H, m), 7.52(1H, d, J=3.0Hz), 7.60-7.90(3H, m), 8.10(1H, d, J=6.75Hz), 8.43(1H, s), 8.75 (1H, d, J=6.75Hz), 11.40(1H, d, J=8.5Hz). (DMSO-d ₆)

Table 7 (continued)

Compound No.	m.p. (°C)	NMR (δ value)
2-201	237~238	6.72(1H,d,J=8.5Hz), 7.05-7.27(2H,m), 7.45-7.95(6H,m), 8.13(1H,dd,J=6.75, 1.5Hz), 8.55(1H,s), 8.80(1H,dd,J=6.75, 1.5Hz), 11.26(1H,d,J=8.5Hz). (DMSO-d ₆)
2-202	91~94	1.03 1.37(6H,m), 1.47 3.00(4H,m), 6.82(1H,d,J=7.5Hz), 7.05-7.31(4H,m), 7.38-7.49(1H,m), 7.52-7.61(1H,m), 7.63-7.76(1H,m), 8.15(1H,d,J=1.35, 7.5Hz), 8.38(1H,s), 8.88(1H,dd,J=1.35, 6.95Hz), 11.21(1H,d,J=7.5Hz). (DMSO-d ₆)
2-203	189~190	2.54(3H,s), 6.75(1H,d,J=8.5Hz), 7.05-7.40(4H,m), 7.48(1H,m), 7.70(1H,m), 7.93(1H,m), 8.25(1H,d,J=6.75Hz), 8.50(1H,s), 8.85(1H,d,J=6.75Hz), 11.12(1H,d,J=8.5Hz). (DMSO-d ₆)
2-204	141~142	1.18(3H,t,J=7.8Hz), 2.44(3H,s), 2.60(2H,q,J=7.8Hz), 6.77(1H,d,J=7.2Hz), 7.02-7.30(3H,m), 7.40-7.52(1H,m), 7.63-7.77(2H,m), 8.13(1H,dd,1.35, 7.5Hz), 8.41(1H,s), 8.83(1H,dd,J=1.35, 6.75Hz), 11.28(1H,d,J=7.2Hz). (DMSO-d ₆)
2-209	195~197	2.62(3H,s), 2.81(3H,s), 6.65(1H,d,J=8.5Hz), 6.90-7.50(5H,m), 7.80-8.15(3H,m), 8.42(1H,s), 8.78(1H,d,J=6.75Hz), 11.08(1H,d,J=8.5Hz). (DMSO-d ₆)

Table 7 (continued)

Compound No.	m.p.(°C)	NMR (δ value)
2-210	237~238	2.61(3H,s), 3.22(3H,s), 6.74(1H,d,J=8.5Hz), 7.05-7.35(2H,m), 7.48(1H,m), 7.65-8.22(5H,m), 8.58(1H,s), 8.88(1H,d,J=6.75Hz), 11.18(1H,d,J=8.5Hz). (DMSO-d ₆)
2-211	201~202	2.30(3H,s), 3.94(3H,s), 6.49(1H,d,J=7.5Hz), 6.91(1H,t,J=7.5Hz), 7.00-7.30(3H,m), 7.35-7.52(3H,m), 7.89(1H,d,J=2.0Hz), 8.22(1H,s), 8.18(1H,dd,J=7.5, 1.5Hz), 8.25(1H,dd,J=7.5, 1.5Hz), 11.62(1H,d,J=7.5Hz). (CDCl ₃)
2-212	244~245	4.00(3H,s), 6.50(1H,d,J=7.5Hz), 6.99-7.35(3H,m), 7.48-7.61(2H,m), 8.05-8.25(2H,m), 8.42(1H,s), 8.59(1H,dd,J=7.5, 1.5Hz), 11.29(1H,d,J=7.5Hz). (DMSO-d ₆ +CDCl ₃)
2-213	138~139	1.10-1.40(12H,m), 2.75-3.15(1H,m), 3.55-3.90(1H,m), 6.82(1H,d,J=8.5Hz), 7.05-7.70(7H,m), 8.18(1H,d,J=6.75Hz), 8.23(1H,s), 8.89(1H,d,J=6.75Hz), 11.20(1H,d,J=8.5Hz). (DMSO-d ₆)
2-214	153~154	1.12-1.31(6H,m), 1.30(3H,d,J=6.0Hz), 2.70-3.18(1H,m), 3.40-3.70(1H,m), 6.67(1H,d,J=8.5Hz), 6.90-7.20(2H,m), 7.70(1H,s), 8.15-8.40(2H,m), 11.42(1H,d,J=8.5Hz). (CDCl ₃)

Table 7 (continued)

Compound No.	m.p.(°C)	NMR (δ value)
2-215	207~209	1.32(3H,d,J=7.5Hz), 2.75-3.15(1H,m), 6.55(1H,d,J=7.5Hz), 6.98(1H,t,J=6.0Hz), 7.08-7.18(1H,m), 7.28(1H,d,J=8.5Hz), 7.35-7.55(2H,m), 7.75(2H,d,J=8.5Hz), 7.89(1H,s), 8.20(1H,dd,J=6.0, 1.5Hz), 8.25(1H,dd,J=6.0, 1.5Hz), 11.60(1H,d,J=7.5Hz). (CDCl ₃)
2-230	215~217	2.28(3H,s), 6.40-6.75(3H,m), 7.00-7.60(5H,m), 8.30(1H,d,J=6.75Hz), 9.75(1H,d,J=7.0Hz). (DMSO-d ₆)
2-231	175~176	6.50(1H,d,J=7.5Hz), 7.05-7.15(1H,m), 7.35-7.50(4H,m), 7.80-8.00(1H,m), 7.85(1H,d,J=4.5Hz), 8.32(1H,s), 8.50(1H,d,J=4.5Hz), 11.12(1H,d,J=7.5Hz). (CDCl ₃)
2-232	209~210	6.48(1H,d,J=7.5Hz), 7.05-7.20(1H,m), 7.35-7.55(4H,m), 7.75-7.95(1H,m), 7.82(1H,s), 8.38(1H,s), 10.98(1H,d,J=7.5Hz). (CDCl ₃)

Formulation Example 1

Emulsifiable concentrates, as prepared by blending the following components:

Compound No. 2-2	20% (by weight)
xylene	75%
polyoxyethylenealkylaryl ether (Nonipol 85 ^R)	5%

Formulation Example 2


Wettable powders, as prepared by blending and grinding the following components:

Compound No. 2-24	50% (by weight)
diatomaceous earth	44%
polyoxyethylenealkylaryl ether (Nonipol 85 ^R)	6%

Formulation Example 3	
Powders, as prepared by blending the following mixture:	
Compound No. 2-27	3% (by weight)
clay	40%
talc	57%


Claims

1. A condensed heterocyclic compound of the formula:




wherein Q is a condensed heterocyclic group having a nitrogen atom in the bridgehead which is unsubstituted or substituted, X is a hydrogen atom or a group attached through C, O, S or N, and Y is an electron attractive group, or its salt.

2. A compound of claim 1 wherein the condensed heterocyclic group having a nitrogen atom in the bridgehead which is unsubstituted or substituted is a group represented by the formula:




in which A is a group forming a condensed ring at the [1,2] positions of the imidazole ring, A' is a group forming a condensed ring at the [1,5] positions of the imidazole ring, A'' is a group forming a condensed ring at the [1,5] positions of the pyrazole ring, A''' is a group forming a condensed ring at the [1,2] positions of the pyrrole ring, A'''' is a group forming a condensed ring at the [3,4] positions of the triazole ring, and B¹, B² and B³ may be the same or different and are a hydrogen, nitro, amino, hydroxyl, cyano, C₁₋₃ acyl, carbamoyl, carboxyl, alkoxy, sulfo, halogen, C₁₋₄ alkoxy, C₆₋₁₀ aryloxy, C₆₋₁₀ aryl-carbonyl, C₆₋₁₀ aryl, C₇₋₁₀ aralkyl, C₃₋₇ cycloalkyl, C₁₋₄ alkylthio, C₆₋₁₀ arylthio, C₇₋₁₀ aralkylthio, mono- or di-alkylsulfamoyl, C₁₋₆ alkyl, substituted phenyl or aromatic heterocyclic group.

3. A compound of claim 2 wherein the condensed ring represented by



as the skeleton of the formula:




is an imidazo [1,2-a]pyridine.

4. A compound of claim 1 wherein the group X attached through C is an alkyl, alkenyl, haloalkyl, cycloalkyl, cycloalkenyl, aryl or aralkyl group or an aromatic heterocyclic group having a chemical bond at a carbon atom.


5. A compound of claim 4 wherein the aromatic heterocyclic group having a chemical bond at a carbon atom, is furyl, thienyl or pyrazolyl group.

6. A compound of claim 1 wherein the electron attractive group Y is cyano, carbamoyl, thiocarbamoyl or trichloromethyl group.

7. A compound of claim 1 which is represented by the formula:




wherein Q'' is



in which B¹'' is a phenyl or substituted phenyl group and B²'' is a hydrogen atom or a C₁₋₆ alkyl group; and X'' is a phenyl, fluorine-substituted phenyl, thienyl or furyl group, or its salt.

8. A compound of claim 7 wherein Q'' is




wherein n is 0, 1, 2, 3 or 4 and 1 is the same or different and selected from a group comprising a C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkylthio or halogen.

9. A compound of claim 1 which is α-(2-phenylimidazo[1,2-a]pyridin-8-ylcarbonylamino)-(2-thienyl)-acetonitrile or its salt.

10. A method for preparing a condensed heterocyclic compound of the formula (I) in claim 1 or its salt which comprises reacting a compound of the formula
Q-CO-Z (II)

wherein Q has the same meaning as defined in claim 1 and Z is a leaving group, or its salt with a compound of the general formula




wherein X and Y are each as defined in claim 1, or its salt.

11. A fungicidal composition comprising a condensed heterocyclic compound of the formula (I) in claim 1 or its salt, and a carrier or diluent.


12. A condensed heterocyclic carboxylic acid compound of the formula:

$\text{Q}^1\text{-CO-Z}$ (IV)

wherein Q^1 is a condensed heterocyclic group having a nitrogen atom in the bridgehead as follows



in which R^1 is an C_{1-6} alkyl, halogen C_{1-4} alkoxy, C_{1-4} alkylthio, C_{6-10} aryloxy, C_{6-10} arylthio, alkoxycarbonyl, phenyl, substituted phenyl or aromatic heterocyclic group; R^2 and R^3 are a hydrogen, C_{1-6} alkyl, halogen, nitro, amino, sulfo, mono- or di-alkylsulfamoyl, alkoxycarbonyl, formyl, cyano, phenyl, substituted phenyl or aromatic heterocyclic group, provided that when Q^1 is




and R^1 is $\text{COOCH}_2\text{CH}_3$, either one of R^2 and R^3 is another group than hydrogen atom, and Z is a leaving group;

or its salt.

13. A process for preparing a compound of the formula

$\text{Q}^2\text{-CO-Z}$ (VIII)

wherein Q^2 is a group of the general formula:




in which R¹, R² and R³ have the same meanings as defined in claim 11 or its salt which comprises reacting a compound of the formula:




wherein the ring (A) is a pyridine, pyridazine, pyrimidine or pyrazine group which is unsubstituted or substituted by an C₁₋₆ alkyl, halogen, nitro, amino, sulfo, mono- or di-alkylsulfamoyl, alkoxycarbonyl, formyl, cyano, phenyl, substituted phenyl or aromatic heterocyclic group, and Z is a leaving group, or its salt

with a compound of the formula:



or



45 wherein W is a halogen atom, and R¹ and R² have the same meanings as defined above.

14. Use of a compound as claimed in claims 1 to 9 as fungicide more particularly for controlling various kinds of plant blight such as downy mildew and blight.

50

55



Application number

DOCUMENTS CONSIDERED TO BE RELEVANT			EP 90111903.2
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int Cl ⁷)
A	<u>EP - A2/A3 - 0 238 070</u> (TAKEDA) * Abstract; pages 5-14 *	1, 11, 12, 14	C 07 D 471/04 C 07 D 487/04 C 07 D 513/04 C 07 D 498/04
D, A	<u>GB - A - 2 190 375</u> (MITSUI) * Claims 1, 7, 8 *	1-14	A 01 N 43/90 /(C 07 D 471/04 C 07 D 235/00 C 07 D 221/00)
	CHEMICAL ABSTRACTS, vol. 103, no. 7, August 19, 1985, Colum- bus, Ohio, USA SIGOVA, V.I. et al. "Synthesis and biological activity of the aryl amides of 2-methyl- nicotinic and 2-phenylindoli- sine-8-carboxylic acids" page 563, column 1, abstract-no. 53 910y & Khim. Pharm. Zh. 1985, 19(3), 159-63 -----	1	
			TECHNICAL FIELDS SEARCHED (Int Cl ⁷)
			C 07 D 471/00 C 07 D 487/00 C 07 D 513/00 C 07 D 498/00
The present search report has been drawn up for all claims			
Place of search VIENNA		Date of completion of the search 14-08-1990	Examiner ONDER
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons</p> <p>& : member of the same patent family, corresponding document</p>			